Inventor Search

=> d ibib abs hitstr l17 1-1

L17 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:725654 HCAPLUS
DOCUMENT NUMBER: 133:276337
TITLE: Compound for inhibiting the influx of polymorphonuclear leukocytes (PMNs) in a tissue, its selection, pharmaceutical compositions and use
INVENTOR(S): **Nijkamp, Franciscus Petrus; Pfister, Rosswell Robert; Haddox, Jeffrey Lynn; Blalock, James Edwin; Villain, Matteo**
PATENT ASSIGNEE(S): Centre for Immunopharmacology, Neth.
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059931	A1	20001012	WO 2000-NL225	20000406
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
NL 1011737	C2	20001009	NL 1999-1011737	19990406
EP 1131341	A1	20010912	EP 2000-917492	20000406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2004176304	A1	20040909	US 2003-712985	20031113

PRIORITY APPLN. INFO.:

NL 1999-1011737	A	19990406
WO 2000-NL225	W	20000406
US 2002-958049	B1	20020404

OTHER SOURCE(S): MARPAT 133:276337

AB The invention relates to a compound suitable for inhibiting the influx of polymorphonuclear leukocytes (PMNs) into a tissue involved in a chronic inflammatory disease. The compound according to the invention is capable of forming a complex with N-acetyl-Pro-Gly-Pro. The invention also relates to a method of selecting such a compound, a pharmaceutical composition and an application of the compound The tetrameric peptide, ((H2N-RTRGG)2K)2KA, inhibited induction of lung emphysema by N-AcPGP in mice.

IT **292171-05-2**
RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)
(compound inhibiting influx of polymorphonuclear leukocytes in tissues for treating chronic inflammatory disease)

RN 292171-05-2 HCAPLUS
CN L-Proline, 1-methyl-L-prolylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

=> d ibib abs hitstr l18 1-44

L18 ANSWER 1 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:934471 HCAPLUS
DOCUMENT NUMBER: 141:388765
TITLE: Disease prevention and vaccination following thymic reactivation
INVENTOR(S): Boyd, Richard
PATENT ASSIGNEE(S): Norwood Immunology, Ltd., Australia
SOURCE: PCT Int. Appl., 210 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 19
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094599	A2	20041104	WO 2004-US11913	20040419 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004013641	A1	20040122	US 2003-418727	20030418 <--
US 2004018180	A1	20040129	US 2003-418747	20030418 <--
US 2004037817	A1	20040226	US 2003-419066	20030418 <--
US 2004241842	A1	20041202	US 2003-748450	20031230 <--
PRIORITY APPLN. INFO.:			US 2003-418727 A	20030418 <--
			US 2003-418747 A	20030418 <--
			US 2003-419066 A	20030418 <--
			US 2003-419068 A	20030418 <--
			US 2003-527001P P	20031205
			US 2003-748450 A	20031230
			US 2003-748831 A	20031230
			US 2003-749118 A	20031230
			US 2003-749122 A	20031230
			AU 1999-9778 A	19990415 <--
			WO 2000-AU329 A2	20000417 <--
			AU 2000-745 A	20001013 <--
			US 2000-795286 B2	20001013 <--
			US 2000-795302 B2	20001013 <--
			US 2001-755646 B2	20010105 <--
			US 2001-755965 B2	20010105 <--
			US 2001-755983 B2	20010105 <--
			US 2001-758910 B2	20010110 <--
			US 2001-965394 A2	20010926 <--
			US 2001-965395 B2	20010926 <--
			US 2001-966575 B2	20010926 <--
			US 2001-976598 A2	20011012 <--
			US 2001-976599 A2	20011012 <--
			US 2001-977479 A2	20011012 <--
			WO 2001-AU1291 A	20011015 <--

AB The invention provides methods for preventing or **treating**

illness, improving responsiveness to immunization, and improving the efficacy of gene **therapy** in a patient, by disrupting sex steroid mediated signaling and reactivating the patient's thymus. In some embodiments, the patient's thymus is reactivated by interruption or ablation of sex steroid mediated signaling by the administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines, anti-androgens, anti-estrogens, selective estrogen receptor modulators (SERMs), selective androgen receptor modulators (SARMs), selective progesterone response modulators (SPRMs), ERDs, aromatase inhibitors, or various combinations thereof.

IT **132326-72-8**
RL: PRP (Properties)
(unclaimed sequence; disease prevention and vaccination following thymic reactivation)

RN 132326-72-8 HCAPLUS

CN L-Valine, L-threonyl-L-tyrosyl-L-glutaminyl-L-arginyl-L-threonyl-L-arginyl-L-alanyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L18 ANSWER 2 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:113519 HCAPLUS
DOCUMENT NUMBER: 140:162359
TITLE: Nucleic acid vaccines against infection, cancer and **autoimmune** disease and targeted gene delivery to antigen-presenting cells
INVENTOR(S): Craig, Roger K.

PATENT ASSIGNEE(S): M.L. Laboratories Plc, UK
SOURCE: U.S., 61 pp., Cont.-in-part of U.S. Ser. No. 22,614, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 6689757	B1	20040210	US 1998-221050		19981228	<--
PRIORITY APPLN. INFO.:			GB 1996-2777	A	19960212	<--
			US 1996-16506P	P	19960430	<--
			GB 1996-14548	A	19960711	<--
			US 1996-24116P	P	19960816	<--
			US 1997-800079	B2	19970212	<--
			US 1997-861283	B1	19970521	<--
			US 1998-22614	B2	19980212	<--

AB The invention relates to methods of and compns. for vaccinating a mammal against a disease, wherein a mixture is administered which includes (i) a nucleic acid which encodes a first epitope and (ii) a peptide containing a second epitope such that both of the nucleic acid and the second epitope are taken up by and the nucleic acid is expressed in a professional antigen presenting cell of the mammal, and the first and second epitopes are processed in the cell such that an immune response is elicited in the mammal to the epitopes. The nucleic acid vaccine encodes antigen, tumor antigen or autoantigen for use to **treat** infection, cancer and **autoimmune** disease. The targeted gene delivery to APCs, their stem cell or other precursor cell are achieved by receptor-mediated gene transfer. The targeting ligands may be anti-CD34 monoclonal antibody, stem cell factor or flk-2 ligand for hematopoietic stem cells; anti-CD33 monoclonal antibody for monocyte or macrophage or dendritic cell; etc.

IT **132326-72-8**
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleic acid vaccines against infection, cancer and **autoimmune** disease and targeted gene delivery to antigen-presenting cells)

RN 132326-72-8 HCAPLUS
CN L-Valine, L-threonyl-L-tyrosyl-L-glutaminyl-L-arginyl-L-threonyl-L-arginyl-L-alanyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 93 THERE ARE 93 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:950457 HCAPLUS
DOCUMENT NUMBER: 140:26909
TITLE: Antibodies that immunospecifically bind to BLyS and their use in diagnosis and **treatment** of **autoimmune** disease
INVENTOR(S): Ruben, Steven M.; Barash, Steven C.; Choi, Gil H.; Vaughan, Tristan; Hilbert, David
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 186 pp., Cont.-in-part of U.S. Ser. No. 880,748.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2003223996	A1	20031204	US 2002-293418		20021114 <--
US 2003059937	A1	20030327	US 2001-880748		20010615 <--
JP 2004129667	A2	20040430	JP 2003-362615		20031022 <--
PRIORITY APPLN. INFO.:			US 2000-212210P	P	20000616 <--
			US 2000-240816P	P	20001017 <--

US 2001-276248P	P	20010316 <--
US 2001-277379P	P	20010321 <--
US 2001-293499P	P	20010525 <--
US 2001-880748	A2	20010615 <--
US 2001-331469P	P	20011116 <--
US 2001-340817P	P	20011219 <--
JP 1998-520411	A3	19961025 <--

AB The present invention relates to antibodies and related mols. that immunospecifically bind to BLyS (B lymphocyte stimulator). The present invention also relates to methods and compns. for detecting or diagnosing a disease or disorder associated with aberrant BLyS expression or inappropriate function of BLyS comprising antibodies or fragments or variants thereof or related mols. that immunospecifically bind to BLyS. The present invention further relates to methods and compns. for preventing, **treating** or ameliorating a disease or disorder associated with aberrant BLyS expression or inappropriate BLyS function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related mols. that immunospecifically bind to BLyS.

IT **389116-54-5**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; antibodies that immunospecifically bind to BLyS and their use in diagnosis and **treatment** of **autoimmune** disease)

RN 389116-54-5 HCAPLUS

CN L-Valine, L-α-aspartyl-L-arginyl-L-threonyl-L-arginyl-L-methionyl-L-α-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 4 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:906632 HCAPLUS
Correction of: 2002:736063
DOCUMENT NUMBER: 139:349665

Correction of: 137:277814

TITLE: Modified anaphylactic food allergens with reduced IgE-binding ability for decreasing clinical reaction to allergy

INVENTOR(S): Caplan, Michael; Sosin, Howard; Sampson, Hugh; Bannon, Gary A.; Burks, Wesley A.; Cockrell, Gael; Compadre, Cesar M.; Connaughton, Cathie; Helm, Ricki M.; King, Nina E.; Kopper, Randall A.; Maleki, Sohelia J.; Rabjohn, Patrick A.; Shin, David S.; Stanley, J. Steven

PATENT ASSIGNEE(S): Panacea Pharmaceuticals, USA; et al.

SOURCE: PCT Int. Appl., 299 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 12

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074250	A2	20020926	WO 2002-US9108	20020318 <--
WO 2002074250	A3	20031009		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 765211	B2	20030911	AU 2001-43769	20010508 <--

PRIORITY APPLN. INFO.: US 2001-276822P P 20010316 <--
AU 1996-72433 A3 19960923 <--

AB It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T-cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by altering as little as a single amino acid within the protein, preferably a hydrophobic residue **towards** the center of the IgE epitope, to eliminate IgE binding. Addnl. or alternatively a modified allergen with reduced IgE binding may be prepared by disrupting one or more of the disulfide bonds that are present in the natural allergen. The disulfide bonds may be disrupted chemical, e.g., by reduction and alkylation or by mutating one or more cysteine residues present in the primary amino acid sequence of the natural allergen. In certain embodiments, modified allergens are prepared by both altering one or more linear IgE epitopes and disrupting one or more disulfide bonds of the natural allergen. In certain embodiments, the methods of the present invention allow allergens to be modified while retaining the ability of the protein to activate T-cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity. The Examples provided herein use peanut allergens to illustrate applications of the invention.

IT **191857-20-2**
RL: ANT (Analyte); PRP (Properties); REM (Removal or disposal); ANST (Analytical study); PROC (Process)
(allergens comprising inactivated or deleted IgE-binding epitope and preserved T cell-activating ability for **immunotherapy** of food allergies)

RN 191857-20-2 HCAPLUS
CN Glycine, glycyl-L-α-glutamyl-L-arginyl-L-threonyl-L-arginylglycyl-L-arginyl-L-glutaminyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NH2

—CO2H

PAGE 2-A



L18 ANSWER 5 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:855391 HCAPLUS
DOCUMENT NUMBER: 139:363577
TITLE: Modified anaphylactic food allergens with reduced IgE-binding ability for decreasing clinical reaction to allergy
INVENTOR(S): Caplan, Michael J.; Sosin, Howard B.; Sampson, Hugh; Bannon, Gary A.; Burks, A. Wesley; Cockrell, Gael; Compadre, Cesar M.; Connaughton, Cathie; Helm, Ricki M.; King, Nina E.; Kopper, Randall A.; Maleki, Soheila J.; Rabjohn, Patrick A.; Shin, David S.; Stanley, J. Steven
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 194 pp., Cont.-in-part of U.S. Ser. No. 494,096.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 2003202980	A1	20031030	US 2002-100303		20020318	<--
JP 2002223783	A2	20020813	JP 2001-356754		19960923	<--
US 6486311	B1	20021126	US 1998-106872		19980629	<--
AU 765211	B2	20030911	AU 2001-43769		20010508	<--
PRIORITY APPLN. INFO.:			US 1995-9455P	P	19951229	<--
			US 1996-717933	B1	19960923	<--
			US 1998-73283P	P	19980131	<--
			US 1998-74590P	P	19980213	<--
			US 1998-74624P	P	19980213	<--
			US 1998-74633P	P	19980213	<--
			US 1998-106872	A2	19980629	<--
			US 1998-141220	A2	19980827	<--
			US 1998-191593	A2	19981113	<--
			US 1999-240557	B2	19990129	<--
			US 1999-241101	B2	19990129	<--
			US 1999-248673	B2	19990211	<--
			US 1999-248674	B2	19990211	<--
			US 1999-122450P	P	19990302	<--
			US 1999-122452P	P	19990302	<--
			US 1999-122560P	P	19990302	<--
			US 1999-122565P	P	19990302	<--
			US 1999-122566P	P	19990302	<--
			US 1999-267719	B2	19990311	<--

US 2000-494096	A2	20000128 <--
US 2001-276822P	P	20010316 <--
US 1996-610424	A	19960304 <--
AU 1996-72433	A3	19960923 <--
JP 1997-524311	A3	19960923 <--
WO 1996-US15222	A2	19960923 <--

AB It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T-cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by altering as little as a single amino acid within the protein, preferably a hydrophobic residue **towards** the center of the IgE epitope, to eliminate IgE binding. Addnl. or alternatively a modified allergen with reduced IgE binding may be prepared by disrupting one or more of the disulfide bonds that are present in the natural allergen. The disulfide bonds may be disrupted chemical, e.g., by reduction and alkylation or by mutating one or more cysteine residues present in the primary amino acid sequence of the natural allergen. In certain embodiments, modified allergens are prepared by both altering one or more linear IgE epitopes and disrupting one or more disulfide bonds of the natural allergen. In certain embodiments, the methods of the present invention allow allergens to be modified while retaining the ability of the protein to activate T-cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity. The **immunotherapeutics** can be prepared in transgenic plants or animals; and administered in injection, aerosol, sublingual or topical form. The **immunotherapeutics** can also be encoded in gene for gene **therapy** and delivered by injecting into muscle or skin to induce tolerance. The Examples provided herein use peanut allergens to illustrate applications of the invention.

IT **191857-20-2**
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IgE-binding epitope; modified anaphylactic food allergens with reduced IgE-binding ability for decreasing clin. reaction to allergy)

RN 191857-20-2 HCAPLUS

CN Glycine, glycyl-L-α-glutamyl-L-arginyl-L-threonyl-L-arginylglycyl-L-arginyl-L-glutaminyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-A



IT **291507-41-0 291507-43-2 291507-44-3**
291507-46-5
RL: PRP (Properties)
(unclaimed sequence; modified anaphylactic food allergens with reduced IgE-binding ability for decreasing clin. reaction to allergy)
RN 291507-41-0 HCAPLUS
CN L-Arginine, L-glutaminyl-L-arginyl-L-seryl-L-prolyl-L-prolylglycyl-L-α-glutamyl-L-arginyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 291507-43-2 HCAPLUS
CN L-Arginine, L-seryl-L-prolyl-L-prolylglycyl-L-α-glutamyl-L-arginyl-L-threonyl-L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 291507-44-3 HCAPLUS

CN L-Proline, L-prolylglycyl-L-α-glutamyl-L-arginyl-L-threonyl-L-arginylglycyl-L-arginyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 291507-46-5 HCAPLUS
CN L-Aspartic acid, L-α-glutamyl-L-arginyl-L-threonyl-L-arginylglycyl-L-arginyl-L-glutaminyl-L-prolylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L18 ANSWER 6 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:532743 HCAPLUS
DOCUMENT NUMBER: 139:99852
TITLE: Human anti-BLyS antibodies for diagnosis, prognosis and therapy of autoimmune, inflammatory, infectious and proliferative diseases
INVENTOR(S): Ruben, Steven M.; Barash, Steven C.; Choi, Gil H.; Vaughan, Tristan J.; Hilbert, David
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
SOURCE: PCT Int. Appl., 3099 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055979	A2	20030710	WO 2002-US36496	20021114
WO 2003055979	A3	20031218		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1456347	A2	20040915	EP 2002-802570	20021114
JP 2004129667	A2	20040430	JP 2003-362615	20031022

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

PRIORITY APPLN. INFO.:		
US 2001-331469P	P	20011116
US 2001-340817P	P	20011219
JP 1998-520411	A3	19961025
WO 2002-US36496	W	20021114

AB The present invention relates to antibodies and related mols. that immunospecifically bind to BLyS or B lymphocyte stimulator. The present invention also relates to methods and compns. for detecting or diagnosing a disease or disorder associated with aberrant BLyS expression or inappropriate function of BLyS comprising antibodies or fragments or variants thereof or related mols. that immunospecifically bind to BLyS. The present invention further relates to methods and compns. for preventing, treating or ameliorating a disease or disorder associated with aberrant BLyS expression or inappropriate BLyS function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related mols. that immunospecifically bind to BLyS.

L18 ANSWER 7 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	2002:252502 HCAPLUS
DOCUMENT NUMBER:	136:320369
TITLE:	cDNA and protein sequence of a novel human protein 16 and their uses in drug screening, diagnosis and **therapeutics**
INVENTOR(S):	Mao, Yumin; Xie, Yi
PATENT ASSIGNEE(S):	Bode Gene Development Co., Ltd., Shanghai, Peop. Rep. China
SOURCE:	Faming Zhuanli Shenqing Gongkai Shuomingshu, 31 pp. CODEN: CNXXEV
DOCUMENT TYPE:	Patent
LANGUAGE:	Chinese
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1315423	A	20011003	CN 2000-115233	20000328 <--

PRIORITY APPLN. INFO.:		
CN 2000-115233		20000328 <--

AB This invention provides the cDNA and protein sequence of a novel human protein 16 cloned from fetal brain. The mol. weight of protein 16 is 16 kDa determined on SDS PAGE and the gene distribution pattern for protein 16 is similar to that for zinc finger protein. The invention discloses the

process of screening the agonist and antagonist against the polypeptide. The protein 16 can be used to diagnosis and **treatment** for many diseases e.g. cancers, **inflammation**, immunol. disease, blood diseases and AIDS.

IT **412319-72-3**
RL: PRP (Properties)
(Unclaimed; cDNA and protein sequence of a novel human protein 16 and their uses in drug screening, diagnosis and **therapeutics**)

RN 412319-72-3 HCAPLUS

CN L-Serine, L-methionyl-L-alanyl-L-arginyl-L-arginyl-L-serylglycyl-L-leucyl-L-seryl-L-arginyl-L-threonyl-L-arginyl-L-arginyl-L-cysteinyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B



L18 ANSWER 8 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:757764 HCAPLUS
DOCUMENT NUMBER: 135:317467
TITLE: Method of using human receptor protein 4-1BB
INVENTOR(S): Kwon, Byoung S.
PATENT ASSIGNEE(S): Advanced Research and Technology, USA
SOURCE: U.S., 27 pp., Cont.-in-part of U.S. Ser. No. 409,851, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 6303121	B1	20011016	US 1998-7097	19980114 <--
US 6362325	B1	20020326	US 1993-12269	19930201 <--
CA 2429027	AA	19950323	CA 1994-2429027	19940915 <--
CA 2318525	AA	19990722	CA 1999-2318525	19990114 <--
WO 9936093	A1	19990722	WO 1999-US823	19990114 <--
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9923204	A1	19990802	AU 1999-23204	19990114 <--
AU 764257	B2	20030814		
EP 1045701	A1	20001025	EP 1999-903099	19990114 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002531376	T2	20020924	JP 2000-539866	19990114 <--
US 6569997	B1	20030527	US 2000-578764	20000525 <--
US 2004091476	A1	20040513	US 2001-877338	20010608 <--
US 2002168719	A1	20021114	US 2001-27199	20011220 <--
PRIORITY APPLN. INFO.:			US 1993-12269	A2 19930201 <--
			US 1993-122796	B2 19930916 <--
			US 1995-409851	B2 19950323 <--
			US 1988-267577	B2 19881107 <--
			US 1992-922996	A2 19920730 <--
			CA 1994-2172165	A3 19940915 <--
			US 1995-461652	B1 19950605 <--
			US 1997-955572	A1 19971022 <--
			US 1998-7097	A 19980114 <--
			WO 1999-US823	W 19990114 <--

AB Disclosed herein are the methods of using the H4-1BB protein, ligands to this protein, and various mAbs either directed against H4-1BB or other mols. that can be used **therapeutically.** The nature and importance of the H4-1BB mol. provides the ligands and related co-stimulatory mols. the ability to enhance or suppress T-cell activation and proliferation. By **treating** T-cells that have expressed receptor protein H4-1BB with one of the four anti-H4-1BB monoclonal antibodies disclosed herein activation or inhibition of the immune response is seen. Also disclosed herein is cDNA for the human receptor H4-1BB. The cDNA of the human receptor H4-1BB is about 65 homologous to the mouse cDNA 4-1BB and was isolated by using probes derived from murine cDNA 4-1BB. A fusion protein for detecting cell membrane ligands to human receptor protein H4-1BB was developed. It comprises the extracellular portion of the receptor protein H4-1BB and a detection protein, alkaline phosphatase, bound to the portion of the receptor protein H4-1BB. B-cells that have expressed a ligand to receptor protein H4-1BB can be **treated** with cells that have expressed receptor protein H4-1BB and B-cell proliferation may be induced. The use of H4-1BB to block H4-1BB ligand binding has practical application in the suppression of the immune system during organ transplantation or against **autoimmune** diseases including diabetes, rheumatoid **arthritis**, and lupus. Other applications of this technol. include the development of **therapeutic** methods for the **treatment** of HIV-1 infected individuals, and the **treatment** of cancerous tumors.

IT **230626-69-4**
RL: PRP (Properties)
(unclaimed sequence; method of using human receptor protein 4-1BB)

RN 230626-69-4 HCAPLUS

CN L-Threonine, L-phenylalanyl-L-α-glutamyl-L-arginyl-L-threonyl-L-arginyl-L-seryl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-prolyl-L-cysteinyl-L-seryl-L-asparaginyl-L-cysteinyl-L-prolyl-L-alanylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B



PAGE 2-C



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 9 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:747623 HCAPLUS
DOCUMENT NUMBER: 135:287522
TITLE: Composition for **treatment** of **autoimmune** disease
INVENTOR(S): Solvason, Nanette Wardy; Mocci, Simonetta
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074375	A1	20011011	WO 2001-US11298	20010404 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-194547P P 20000404 <--
US 2000-247117P P 20001110 <--

AB The present invention provides novel compns. and methods for inhibiting immune responses associated with **autoimmune** diseases and allergic responses. In particular, it relates to vaccination with compns. comprising an adjuvant comprising cell wall skeleton ("CWS") from a Mycobacterium sp. and peptides from the hypervariable region of MHC mols. encoded by alleles associated with disease.

IT **287178-26-1 365400-42-6 365400-44-8**
RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(Mycobacterium peptide and cell wall skeleton compns. for **treatment** of **autoimmune** disease)

RN 287178-26-1 HCAPLUS

CN L-Alanine, glycyl-L-arginyl-L-histidyl-L-seryl-L-alanyl-L-α-glutamyl-L-tyrosyl-L-tyrosyl-L-asparaginyl-L-lysyl-L-glutaminyl-L-tyrosyl-L-leucyl-L-α-glutamyl-L-arginyl-L-threonyl-L-arginyl-L-alanyl-L-α-glutamyl-L-leucyl-L-α-aspartyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 365400-42-6 HCAPLUS
CN L-Aspartic acid, glycyl-L-prolyl-L-prolyl-L-α-aspartyl-L-alanyl-L-α-glutamyl-L-tyrosyl-L-tryptophyl-L-asparaginyl-L-seryl-L-glutaminyl-L-lysyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-arginyl-L-threonyl-L-arginyl-L-alanyl-L-α-glutamyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B

$-CO_2H$

PAGE 3-A



RN 365400-44-8 HCAPLUS
CN L-Aspartic acid, glycyl-L-prolyl-L-prolyl-L-alanyl-L-alanyl-L-α-

glutamyl-L-tyrosyl-L-tryptophyl-L-asparaginyl-L-seryl-L-glutaminyl-L-lysyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-arginyl-L-threonyl-L-arginyl-L-alanyl-L-α-glutamyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 3-A



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 10 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:730951 HCAPLUS
DOCUMENT NUMBER: 135:284037
TITLE: Protein and cDNA sequences of 13 kDa human NAD-dependent 2-hydroxy acid dehydrogenase and

therapeutic use thereof
INVENTOR(S): Mao, Yumin; Xie, Yi
PATENT ASSIGNEE(S): Shanghai Biowindow Gene Development Inc., Peop. Rep. China
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072982	A1	20011004	WO 2001-CN461	20010326 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CN 1315420	A	20011003	CN 2000-115228	20000328 <--
AU 2001056083	A5	20011008	AU 2001-56083	20010326 <--
PRIORITY APPLN. INFO.:			CN 2000-115228 A	20000328 <--
			WO 2001-CN461 W	20010326 <--

AB The invention provides protein and cDNA sequences for 13 kDa novel human protein cloned from fetal brain, and which have similar expression pattern with human NAD-dependent 2-hydroxy acid dehydrogenase 9. The invention also relates to constructing NAD-dependent 2-hydroxy acid dehydrogenase gene expression vectors to prepare recombinant NAD-dependent 2-hydroxy acid dehydrogenase protein using prokaryote or eukaryote cells. Methods of expressing and preparing recombinant NAD-dependent 2-hydroxy acid dehydrogenase protein and its antibody are described. Methods of using NAD-dependent 2-hydroxy acid dehydrogenase gene or protein products for the **treatment** of various kinds of diseases, such as cancer, blood diseases, HIV infection, immune diseases and **inflammation** are also disclosed.

IT **364612-90-8**
RL: PRP (Properties)
(unclaimed sequence; protein and cDNA sequences of 13 kDa human NAD-dependent 2-hydroxy acid dehydrogenase and **therapeutic** use thereof)

RN 364612-90-8 HCAPLUS
CN L-Glutamic acid, L-methionyl-L-cysteinyl-L-leucyl-L-leucyl-L-lysyl-L-isoleucyl-L-prolylglycyl-L-prolyl-L-arginyl-L-threonyl-L-arginyl-L-glutaminyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 11 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:661571 HCAPLUS
DOCUMENT NUMBER: 135:222356
TITLE: Methods of constructing live influenza vaccine by recombination of NS gene of influenza A viruses
INVENTOR(S): Ferko, Boris; Egorov, Andre; Voglauer, Regina
PATENT ASSIGNEE(S): Polymun Scientific Immunbiologische Forschung G.m.b.H., Austria
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064860	A2	20010907	WO 2001-EP2392	20010302 <--
WO 2001064860	A3	20020221		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1259629 A2 20021127 EP 2001-923624 20010302 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2003147916 A1 20030807 US 2002-204664 20021030 <--

US 6800288 B2 20041005

PRIORITY APPLN. INFO.: EP 2000-104338 A 20000302 <--

WO 2001-EP2392 W 20010302 <--

AB The invention provides methods of constructing attenuated live influenza vaccine by recombination of NS gene of an influenza A/PR/8/34 virus. The recombinant NS gene comprises a functional RNA binding domain and a gene sequence modification after nucleotide position 400, wherein the modification bars transcription of the remaining portion of the gene segment. The invention further relates to the modification that comprises deletions, insertions, or a shift of the open reading frame, and particularly to constructs comprising an insertion of an autocleavage site 2A, the nef gene from HIV-1 or the sequence encoding the ELDKWA-epitope of gp41 of HIV-1. The invention also provides influenza virus transfectants that contain the modified NS gene and have an IFN inducing phenotype but which may or may not be sensitive **towards** IFN. The invention also relates to vaccines comprising such a chimeric virus.

IT **358368-78-2**

RL: PRP (Properties)

(unclaimed sequence; methods of constructing live influenza vaccine by recombination of NS gene of influenza A viruses)

RN 358368-78-2 HCAPLUS

CN L-Aspartic acid, L-threonyl-L-tyrosyl-L-glutaminyl-L-arginyl-L-threonyl-L-arginyl-L-alanyl-L-leucyl-L-valyl-L-arginyl-L-threonyl-L-methionylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L18 ANSWER 12 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:541658 HCAPLUS
DOCUMENT NUMBER: 135:133130
TITLE: Protein and cDNA sequences of human apoptin-associating proteins and their uses in cancer **therapy**
INVENTOR(S): Noteborn, Mathieu Hubertus Maria; Danen-van Oorschot, Astrid Adriana Maria; Rohn, Jennifer Leigh; Weiss, Bertram
PATENT ASSIGNEE(S): Leadd B.V., Neth.
SOURCE: Eur. Pat. Appl., 32 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1118662	A2	20010725	EP 2001-200163	20010117 <--
EP 1118662	A3	20010919		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1120463	A1	20010801	EP 2000-200169	20000117 <--
R: DE, SI, LT, LV, RO				

PRIORITY APPLN. INFO.: EP 2000-200169 A 20000117 <--
EP 2000-250118 A 20000407 <--

AB The invention provides protein and cDNA sequences of apoptosis-regulating proteins, designated as APP-2 and APP-3 (apoptin-associating protein 2 and 3). The invention provides novel **therapeutic** possibilities, for example novel combinatorial **therapies** or novel **therapeutic** compds. that can work alone, sequentially to, or jointly with apoptin, especially in those cases wherein p53 is (partly)

non-functional.

IT **351538-30-2**
RL: PRP (Properties)
(unclaimed sequence; protein and cDNA sequences of human apoptin-associating proteins and their uses in cancer **therapy**)

RN 351538-30-2 HCAPLUS

CN L-Aspartic acid, L-threonylglycyl-L-seryl-L-arginyl-L-threonyl-L-arginylglycyl-L-arginyl-L-tryptophyl-L-lysyl-L-tyrosyl-L-seryl-L-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 3-A



L18 ANSWER 13 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:50804 HCAPLUS
DOCUMENT NUMBER: 134:96934
TITLE: Urotensin II-like peptides from rat and mouse, as G-Protein-Coupled Orphan Receptor, SENR (GPR14) ligand, cDNA, and uses in drug screening, diagnosis and **therapy**
INVENTOR(S): Sugo, Tsukasa; Kurihara, Mika; Kitada, Chieko; Mori, Masaaki
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001004298	A1	20010118	WO 2000-JP4484	20000706 <--

W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ,

LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO,
RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

JP 2001069996 A2 20010321 JP 2000-211996 20000707 <--
PRIORITY APPLN. INFO.: JP 1999-194091 A 19990708 <--

AB A urotensin II-like peptide originating in rat or mouse which is an SENR (sensory epithelium neuropeptide-like receptor) ligand or its salt; a nucleic acid encoding this SENR ligand; a method/kit for screening a compound capable of altering the binding properties of the SENR ligand to SENR, etc., are disclosed. DNA encoding the above-described polypeptide or the polypeptide is usable in: (1) searching the physiol. effects of the above polypeptide; (2) constructing synthetic oligonucleotide probes or PCR primers; (3) acquiring DNA encoding an SENR ligand or a precursor protein; (4) developing a receptor-binding assay system and screening candidate compds. for drugs by using a recombinant receptor protein expression system; (5) acquiring an antibody and an antiserum; (6) developing diagnostics with the use of the DNA, RNA, antibody or antiserum; (7) developing drugs such as central nervous function controlling agents, circulatory function controlling agents and **heart** function controlling agents; (8) gene **therapy**; and the like. Arachidonic acid metabolite release induction, and anti-hypertensive effects of those peptides were demonstrated. Synthesis of radioisotope labeled peptides and their use in SENR binding assays are described.

IT **318284-15-0P 318284-17-2P**
RL: ARU (Analytical role, unclassified); BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
(amino acid sequence; urotensin II-like peptides from rat and mouse, as G-Protein-Coupled Orphan Receptor, SENR (GPR14) ligand, cDNA, and uses in screening, diagnosis and **therapy**)

RN 318284-15-0 HCAPLUS
CN L-Isoleucine, L-leucyl-L-leucyl-L-alanyl-L-arginyl-L-threonyl-L-arginyl-L-lysyl-L-glutaminyl-L-arginyl-L-lysyl-L-glutaminyl-L-histidylglycyl-L-threonyl-L-alanyl-L-prolyl-L-α-glutamyl-L-cysteinyl-L-phenylalanyl-L-tryptophyl-L-lysyl-L-tyrosyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 3-A



PAGE 3-B

Bu-i

RN 318284-17-2 HCAPLUS
CN L-Isoleucine, L-leucyl-L-leucyl-L-alanyl-L-arginyl-L-threonyl-L-arginyl-L-lysyl-L-glutaminyl-L-histidyl-L-lysyl-L-glutaminyl-L-histidylglycyl-L-alanyl-L-alanyl-L-prolyl-L-α-glutamyl-L-cysteinyl-L-phenylalanyl-L-tryptophyl-L-lysyl-L-tyrosyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B





PAGE 2-C



PAGE 3-A



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 14 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:881298 HCAPLUS
DOCUMENT NUMBER: 134:38627
TITLE: Human U12-spliceosome-associated 35-kilodalton protein and cDNA and their use in **therapy** and diagnosis
INVENTOR(S): Bauer, Bettina; Luhrmann, Reinhard; Will, Cindy
PATENT ASSIGNEE(S): Aventis Research and Technologies GmbH and Co. KG, Germany
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000075309	A1	20001214	WO 2000-EP3949	20000503 <--
W: AU, CA, IL, JP, NO, NZ, PL, RO, SG, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19925668	A1	20010315	DE 1999-19925668	19990604 <--
CA 2376055	AA	20001214	CA 2000-2376055	20000503 <--
EP 1190049	A1	20020327	EP 2000-931102	20000503 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO				
JP 2003501085	T2	20030114	JP 2001-502573	20000503 <--
NO 2001005906	A	20020204	NO 2001-5906	20011203 <--
PRIORITY APPLN. INFO.:			DE 1999-19925668 A	19990604 <--
			WO 2000-EP3949 W	20000503 <--

AB The invention relates to a human 35-kilodalton spliceosome protein that is associated with the U11/U12 snRNP complex of the U12-dependent spliceosome and that is specific to said spliceosome. Said protein and the DNA sequence encoding it are useful for the **treatment** and diagnosis of certain **autoimmune** diseases, viral infections, cancers, and diseases that are caused by defects in the splicing apparatus

IT **312908-18-2**
RL: PRP (Properties)
(unclaimed sequence; human U12-spliceosome-associated 35-kilodalton

protein and cDNA and their use in **therapy** and diagnosis)

RN 312908-18-2 HCAPLUS

CN L-Aspartic acid, L-lysyl-L-arginyl-L-tryptophyl-L-arginyl-L-threonyl-L-arginyl-L-valyl-L-tryptophyl-L-α-aspartyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A





REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 15 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:842264 HCAPLUS
DOCUMENT NUMBER: 134:13994
TITLE: High-performance enzyme fragment complementation systems for the identification of interacting proteins
INVENTOR(S): Balint, Robert F.; Her, Jeng-Horng
PATENT ASSIGNEE(S): Panorama Research, Inc., USA
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2000071702	A1	20001130	WO 2000-US7108		20000316 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2374476	AA	20001130	CA 2000-2374476		20000316 <--
EP 1183347	A1	20020306	EP 2000-946748		20000316 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2003500051	T2	20030107	JP 2000-620079		20000316 <--
US 2004038317	A1	20040226	US 2003-668778		20030922 <--
PRIORITY APPLN. INFO.:			US 1999-135926P	P	19990525 <--
			US 2000-175968P	P	20000113 <--
			US 1999-124339P	P	19990315 <--

US 2000-526106 A1 20000315 <--
WO 2000-US7108 W 20000316 <--

AB Fragment pairs of a class A β-lactamase (TEM-1 of Escherichia coli) are disclosed that depend for their functional reassembly into the parent protein on the interaction of heterologous polypeptides or other mols. which have been genetically or chemical conjugated to the break-point termini of the fragment pairs. In addition, methods are provided for identifying fragment pairs that will optimally reassemble into a functional parent protein. Fragment pairs that comprise mol. interaction-dependent enzymes find use in (1) homogeneous assays and biosensors for any analyte having two or more independent binding sites, (2) tissue-localized activation of **therapeutic** and imaging reagents in **vivo** for early detection and **treatment** of cancer, chronic **inflammation**, atherosclerosis, amyloidosis, infection, transplant rejection, and other pathologies, (3) cell-based sensors for activation or inhibition of metabolic or signal transduction pathways for high-efficiency, high-throughput screening for agonists/antagonists of the target pathway, (4) high-throughput mapping of pair-wise protein-protein interactions within and between the proteomes of cells, tissues, and pathogenic organisms, (5) rapid selection of antibody fragments or other binding proteins which bind specifically to polypeptides of interest, (6) rapid antigen identification for anti-cell and anti-tissue antibodies, (7) rapid epitope identification for antibodies, (10) cell-based screens for high-throughput selection of inhibitors of any protein-protein interaction.

IT **309718-20-5**
RL: PRP (Properties)
(unclaimed sequence; high-performance enzyme fragment complementation systems for the identification of interacting proteins)

RN 309718-20-5 HCAPLUS

CN L-Cysteine, L-cysteinylglycyl-L-prolyl-L-arginyl-L-threonyl-L-arginyl-L-valyl-L-asparaginyl-L-histidyl-L-glutaminylglycyl-L-glutaminyl-L-lysyl-L-threonyl-L-arginylglycyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 16 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:725654 HCAPLUS
DOCUMENT NUMBER: 133:276337
TITLE: Compound for inhibiting the influx of polymorphonuclear leukocytes (PMNs) in a tissue, its selection, pharmaceutical compositions and use
INVENTOR(S): Nijkamp, Franciscus Petrus; Pfister, Rosswell Robert; Haddox, Jeffrey Lynn; Blalock, James Edwin; Villain, Matteo
PATENT ASSIGNEE(S): Centre for Immunopharmacology, Neth.
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059931	A1	20001012	WO 2000-NL225	20000406 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

NL 1011737	C2	20001009	NL 1999-1011737		19990406 <--
EP 1131341	A1	20010912	EP 2000-917492		20000406 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
US 2004176304	A1	20040909	US 2003-712985		20031113 <--
PRIORITY APPLN. INFO.:			NL 1999-1011737	A	19990406 <--
			WO 2000-NL225	W	20000406 <--
			US 2002-958049	B1	20020404 <--

OTHER SOURCE(S): MARPAT 133:276337

AB The invention relates to a compound suitable for inhibiting the influx of polymorphonuclear leukocytes (PMNs) into a tissue involved in a chronic **inflammatory** disease. The compound according to the invention is capable of forming a complex with N-acetyl-Pro-Gly-Pro. The invention also relates to a method of selecting such a compound, a pharmaceutical composition and an application of the compound The tetrameric peptide, ((H2N-RTRGG)2K)2KA, inhibited induction of lung **emphysema** by N-AcPGP in mice.

IT **300541-35-9P 300541-36-0P**
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compound inhibiting influx of polymorphonuclear leukocytes in tissues for **treating** chronic **inflammatory** disease)

RN 300541-35-9 HCAPLUS

CN L-Alaninamide, N2,N6-bis[N2,N6-bis(L-arginyl-L-threonyl-L-arginylglycylglycyl)-L-lysyl]-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

PAGE 2-B



PAGE 3-A



RN 300541-36-0 HCAPLUS
CN L-Alaninamide, N2,N6-bis[N2,N6-bis(D-arginyl-D-threonyl-D-arginylglycylglycyl)-L-lysyl]-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 3-A



IT **292171-06-3**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(in active compound screening; compound inhibiting influx of polymorphonuclear leukocytes in tissues for **treating** chronic **inflammatory** disease)
RN 292171-06-3 HCAPLUS
CN L-Alanine, N2,N6-bis[N2,N6-bis(L-arginyl-L-threonyl-L-arginylglycylglycyl)-L-lysyl]-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

PAGE 2-B



PAGE 3-A



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 17 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:666624 HCAPLUS
DOCUMENT NUMBER: 133:251267
TITLE: Immunostimulatory nucleic acids and antigens
INVENTOR(S): Sosin, Howard B.; Caplan, Michael J.
PATENT ASSIGNEE(S): Panacea Pharmaceuticals, Llc, USA
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000054803	A2	20000921	WO 2000-US7213	20000316 <--

WO 2000054803 A3 20010111
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-124595P P 19990316 <--
US 1999-125071P P 19990317 <--

AB The present invention provides methods and compns. for modulating an individual's immune response to antigens. It is an aspect of the present invention that allergic responses to antigens, which in some cases lead to **asthma** and even anaphylaxis, can be **treated** or prevented by administering compns. having immunostimulatory oligonucleotides having unmethylated CpG sequences. It is another aspect of the present invention that allergies to antigens, especially one that result in **asthma** and anaphylaxis, can be **treated** or prevented by administering compns. containing immunostimulatory oligonucleotides having unmethylated CpG dinucleotide sequences and further comprising antigen(s), fragments of the antigen, mixts. of fragments of the antigen, antigens modified to reduce Th2-type immune responses, and fragments of the antigen modified to reduce Th2-type immune responses. Cellular systems for studying immunostimulation by CpG containing nucleic acids include in **vivo**, in vitro or ex **vivo** systems.

IT **191857-20-2**
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising unmethylated CpG-containing immunostimulatory oligonucleotides and antigens or allergens for **treating** allergies and **asthma**)

RN 191857-20-2 HCAPLUS

CN Glycine, glycyl-L-α-glutamyl-L-arginyl-L-threonyl-L-arginylglycyl-L-arginyl-L-glutaminyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



L18 ANSWER 18 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:573837 HCAPLUS
DOCUMENT NUMBER: 133:191991
TITLE: Humanized immunoglobulin reactive with B7 molecules and methods of **treatment** therewith
INVENTOR(S): Co, Man Sung; Vasquez, Maximiliano; Carreno, Beatriz; Celniker, Abbie Cheryl; Collins, Mary; Goldman, Samuel; Gray, Gary S.; Knight, Andrea; O'Hara, Denise; Rup, Bonita; Veldman, Geertruida M.
PATENT ASSIGNEE(S): Genetics Institute, Inc., USA
SOURCE: PCT Int. Appl., 162 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047625	A2	20000817	WO 2000-US3303	20000209 <--
WO 2000047625	A3	20010802		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002176855	A1	20021128	US 1999-249011	19990212 <--
CA 2362592	AA	20000817	CA 2000-2362592	20000209 <--
EP 1159300	A2	20011205	EP 2000-919275	20000209 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000008209	A	20020219	BR 2000-8209	20000209 <--
US 6827934	B1	20041207	US 2000-627896	20000727 <--
NO 2001003911	A	20011010	NO 2001-3911	20010810 <--
ZA 2001006982	A	20021211	ZA 2001-6982	20010823 <--

PRIORITY APPLN. INFO.:			
US 1999-249011	A	19990212	<--
US 1999-339596	A2	19990624	<--
WO 2000-US3303	W	20000209	<--

AB The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an Ig of human origin. The invention also pertains to methods of **treatment** for various **autoimmune** diseases,

transplant rejection, **inflammatory** disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.

IT **288390-77-2**
RL: PRP (Properties)
(unclaimed sequence; humanized Ig reactive with B7 mols. and methods of **treatment** therewith)

RN 288390-77-2 HCAPLUS

CN L-Alanine, L-lysyl-L-seryl-L-seryl-L-glutaminyl-L-seryl-L-leucyl-L-leucyl-L-asparaginyl-L-seryl-L-arginyl-L-threonyl-L-arginyl-L-α-glutamyl-L-asparaginyl-L-tyrosyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B



PAGE 3-A



L18 ANSWER 19 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:573818 HCAPLUS
DOCUMENT NUMBER: 133:177491
TITLE: Preparation of peptides inhibiting vascular endothelial cell migration
INVENTOR(S): Shibata, Kenji; Yamasaki, Motoo; Tsukuda, Eiji; Oda, Shoji; Miyamoto, Kaoru
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047606	A1	20000817	WO 2000-JP703	20000209 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2362258	AA	20000817	CA 2000-2362258	20000209 <--

EP 1152011 A1 20011107 EP 2000-902869 20000209 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
PRIORITY APPLN. INFO.: JP 1999-33772 A 19990212 <--
WO 2000-JP703 W 20000209 <--

OTHER SOURCE(S): MARPAT 133:177491

AB Peptides having an activity of inhibiting the migration of vascular endothelial cells represented by the following general formula R1-A-R2 or pharmacol. acceptable salts thereof (wherein R1 represents hydrogen, optionally substituted alkanoyl, optionally substituted aroyl, optionally substituted heteroarylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted aryloxycarbonyl or optionally substituted heteroaryloxycarbonyl; R2 represents hydroxy, optionally substituted alkoxy or optionally substituted amino; and A represents a partial amino acid sequence of the amino acid sequences derived from human, rat, or bovine wherein or more amino acid residues may be substituted, deleted, or added.) are prepared These peptides are useful as remedies for diseases in association with abnormal angiogenesis, for example, solid tumor, **inflammatory** diseases such as **arthritis** and ocular angiogenic diseases such as diabetic retinitis. Thus, H-Leu-Ser-Leu-Trp-Ser-Glu-Trp-Ser-Asp-Ala-Ser-Val-Thr-Ala-Gly-NH2, which was prepared by the solid phase method on Rink Amide MBHA resin using Nα-Fmoc-protected amino acids, in vitro inhibited the migration of endothelial cells of porcine aorta by 41.5±2.1%.

IT **287966-76-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides inhibiting vascular endothelial cell migration as **therapeutics**)

RN 287966-76-1 HCAPLUS

CN L-α-Glutamine, glycyl-L-lysylglycyl-L-histidyl-L-valyl-L-isoleucyl-L-arginyl-L-threonyl-L-arginyl-L-methionyl-L-isoleucyl-L-glutaminyl-L-methionyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 3-A



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 20 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:384402 HCAPLUS
DOCUMENT NUMBER: 133:28919
TITLE: Isoforms of human vanilloid receptors identified by gene discovery and their uses
INVENTOR(S): Delany, Natalie Samantha; Sanseau, Philippe; Tate, Simon Nicholas
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2000032766	A1	20000608	WO 1999-EP9284	19991130	<--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
EP 1135490	A1	20010926	EP 1999-963344	19991130	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
JP 2002531085	T2	20020924	JP 2000-585397	19991130	<--
PRIORITY APPLN. INFO.:			GB 1998-26359 A	19981201	<--
			WO 1999-EP9284 W	19991130	<--

AB The invention provides novel human vanilloid receptor (hVR) proteins, in particular hVR1 and hVR3, nucleotide sequences encoding for the novel hVR proteins, and hVR proteins for use in a method for screening for agents useful in the **treatment** or prophylaxis of disorders which are responsive to modulation of hVr activity in a human patient. The invention also provides expression vectors comprising said nucleotide sequences, stable cell lines comprising said expression vectors, antibodies specific for the novel hVR proteins, methods for the identification of compds. which exhibit hVR modulating activity, compds. identifiable and identified by such methods, and methods of **treatment** or prophylaxis of disorders which are responsive to modulation of hVR activity in a human patient. Candidate genes were identified by BLAST querying of sequence databases with a rat vanilloid receptor sequence. Identification of the gene was confirmed by pharmacol. of the expression product.

IT **273722-46-6**
RL: PRP (Properties)
(unclaimed sequence; isoforms of human vanilloid receptors identified by gene discovery and their uses)

RN 273722-46-6 HCAPLUS

CN L-Cysteine, L-cysteinyl-L-histidyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-threonyl-L-arginyl-L-seryl-L-arginyl-L-threonyl-L-arginyl-L-leucyl-L-phenylalanylglycyl-L-lysylglycyl-L-α-aspartyl-L-seryl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 3-A



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 21 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:368417 HCAPLUS
DOCUMENT NUMBER: 133:9084
TITLE: Retro-inversion peptides that target gastrointestinal tract transport receptors and related methods
INVENTOR(S): O'Mahony, Daniel Joseph
PATENT ASSIGNEE(S): Elan Corporation, Plc, Ire.
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000031123	A2	20000602	WO 1999-IE117	19991119 <--
WO 2000031123	A3	20001109		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2349290 AA 20000602 CA 1999-2349290 19991119 <--
EP 1131344 A2 20010912 EP 1999-972640 19991119 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: US 1998-109038P P 19981119 <--
WO 1999-IE117 W 19991119 <--

AB Digestion-resistant retro-inversion forms of GIT-targeting agents that target specific receptor sites in **vivo** and/or promote uptake of active agents and/or enhance active agent delivery across the GIT into the systemic circulation are provided. These retro-inverted peptides and compns. containing these retro-inverted peptides can be used to deliver an active agent, such as a drug or a drug-containing nano- or microparticles for **treatment** of a condition in a subject in need of the drug, in **vivo**. Addnl., the invention provides antibodies which are capable of immunospecifically binding the retro-inverted peptides.

IT **271588-11-5 271588-14-8**
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(retroinversion peptides that target gastrointestinal tract transport receptors and related methods)

RN 271588-11-5 HCAPLUS

CN D-Threonine, N6-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]-L-lysyl-D-arginyl-D-threonyl-D-arginyl-D-leucyl-D-arginyl-D-arginyl-D-asparaginyl-D-histidyl-D-seryl-D-seryl-D-histidyl-D-lysyl-D-alanyl-D-asparaginyl-, ' (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 271588-14-8 HCAPLUS
CN L-Arginine, N6-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]-L-lysyl-L-threonyl-L-asparaginyl-L-alanyl-L-lysyl-L-histidyl-L-seryl-L-seryl-L-histidyl-L-asparaginyl-L-arginyl-L-arginyl-L-leucyl-L-arginyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



L18 ANSWER 22 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:172837 HCAPLUS
DOCUMENT NUMBER: 132:221339
TITLE: Methods for making HLA binding peptides and their uses
INVENTOR(S): Kubo, Ralph T.; Grey, Howard M.; Sette, Alessandro; Celis, Esteban
PATENT ASSIGNEE(S): Epimmune Inc., USA
SOURCE: U.S., 329 pp., Cont.-in-part of U.S. Ser. No. 103,396, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 6037135	A	20000314	US 1993-159339		19931129	<--
US 5662907	A	19970902	US 1994-186266		19940125	<--
US 2002168374	A1	20021114	US 1997-821739		19970320	<--
US 6689363	B1	20040210	US 1999-239043		19990127	<--
PRIORITY APPLN. INFO.:			US 1992-926666	B2	19920807	<--
			US 1993-27746	B2	19930305	<--
			US 1993-103396	B2	19930806	<--
			US 1992-827682	B2	19920129	<--
			US 1992-874491	B2	19920427	<--
			US 1992-935811	B2	19920826	<--
			US 1993-27146	B2	19930305	<--
			US 1993-73205	B2	19930604	<--
			US 1993-159184	B2	19931129	<--
			US 1993-159339	A2	19931129	<--
			US 1994-197484	A2	19940216	<--
			US 1994-205713	A2	19940304	<--
			US 1994-278634	B2	19940721	<--
			US 1994-344824	A2	19941123	<--
			US 1994-347610	A2	19941201	<--
			US 1995-461603	A1	19950605	<--
			US 1996-13363P	P	19960313	<--
			US 1996-13833P	P	19960321	<--
			US 1997-820360	A2	19970312	<--
			US 1997-978291	A2	19971125	<--
			US 1998-189702	A2	19981110	<--

AB Disclosed are methods for making peptides comprising an HLA-A24.1-, HLA-A1-, HLA-A11-, and HLA-A3.2-restricted T cell epitope consisting of about 8-11 amino acid residues, and methods of making a peptide that binds to an HLA-A24.1, HLA-A1, HLA-A11, and HLA-A3.2 mol. at a dissociation constant of less than 500 nM. Epitopes on a number of potential target proteins (e.g. prostate specific antigen, hepatitis B core and surface antigens, hepatitis C antigen, malignant melanoma antigen MAGE-1, Epstein-Barr virus antigens, HIV-1 and papilloma virus antigen) are identified. These HLA-binding peptides are useful for **treating** and diagnosing a number of pathol. states such as viral infection and cancer.

IT **260984-44-9 260984-50-7 260985-25-9**
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HLA binding epitopes of viral and tumor antigen for **treatment** and diagnosis)

RN 260984-44-9 HCAPLUS

CN L-Arginine, L-seryl-L-alanyl-L-alanyl-L-arginyl-L-seryl-L-seryl-L-arginyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 260984-50-7 HCAPLUS
CN L-Arginine, L-alanyl-L-alanyl-L-arginyl-L-seryl-L-seryl-L-arginyl-L-threonyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 260985-25-9 HCAPLUS
CN L-Arginine, L-arginyl-L-seryl-L-arginyl-L-tyrosyl-L-tryptophyl-L-alanyl-L-isoleucyl-L-arginyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 23 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:764062 HCAPLUS
DOCUMENT NUMBER: 132:10375
TITLE: Agents interfering with the binding of protein

tyrosine phosphatase PEST to domains of signaling proteins as inhibitors of cell migration and/or of focal adhesion

INVENTOR(S): Tremblay, Michel L.; Cote, Jean-Francois; Angers-Lousteau, Alexandre; Charest, Alain

PATENT ASSIGNEE(S): McGill University, Can.

SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9961467	A2	19991202	WO 1999-CA461	19990521 <--
WO 9961467	A3	20000518		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2329157	AA	19991202	CA 1999-2329157	19990521 <--
AU 9939229	A1	19991213	AU 1999-39229	19990521 <--
EP 1077997	A2	20010228	EP 1999-922004	19990521 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002516338	T2	20020604	JP 2000-550871	19990521 <--
CA 2353997	AA	20000622	CA 1999-2353997	19991210 <--
WO 2000036111	A1	20000622	WO 1999-CA1184	19991210 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1137780	A1	20011004	EP 1999-957819	19991210 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002532515	T2	20021002	JP 2000-588360	19991210 <--
US 6534056	B1	20030318	US 1999-466992	19991210 <--

PRIORITY APPLN. INFO.:			
CA 1998-2238654	A	19980521	<--
US 1998-111993P	P	19981211	<--
WO 1999-CA461	W	19990521	<--
WO 1999-CA1184	W	19991210	<--

AB This invention relates to agents or compds. capable of interfering with the binding of protein tyrosine phosphatase PEST to protein domains of signaling mols. involved in cell migration, focal adhesion and/or cell proliferation, namely p130cas and paxillin. The agents can be derived from the minimal sequences found in binding studies. PTP-PEST is a conserved phosphatase essential for embryo development. Knock-out cells (PTP-PEST -/-) have been perpetuated from null embryos and they show defects in cell migration, focal adhesion and cell proliferation.

Therefore, any agent capable of interfering with the activity of PEST in a diseased target tissue, is considered to be a potential **therapeutic** agent to **treat** any disease having any of the following etiol. components: cell proliferation, cancer, metastasis, **inflammation**, and angiogenesis. This invention further relates to a method for finding genuine substrates for enzymes, namely phosphatases, combining gene targeting knock-out technique and substrate-trapping technique with the aid of a substrate binding inactive mutant enzyme. By using a gene targeting knock-out technique, there are less artifacts than by using other techniques (using vanadate compds., for example) wherein an artificial non-specific increase of the level of hyperphosphorylation occurs. Gene targeting of the PTP-PEST suppresses fibroblast motility on the extracellular matrix fibronectin as shown in wound-healing migration assays. Hyperphosphorylation of actin cytoskeleton protein PSTPIP in PEST -/- cells affected the cleavage of furrow formation. This was the first demonstration that the p130cas family of proteins, HefI and Sin interact in a similar manner with a proline rich region found on PTP-PEST with their SH3 domains. It was also shown that PTP-PEST binds to paxillin through its PRO2 region. LIM domains 3 and 4 of paxillin were required for PTP-PEST binding. The design of peptides interfering with the binding of a phosphatase to a signaling protein derived from binding studies is shown.

IT **251362-65-9 251362-66-0**
RL: PRP (Properties)
(unclaimed sequence; agents interfering with the binding of protein tyrosine phosphatase PEST to domains of signaling proteins as inhibitors of cell migration and/or of focal adhesion)

RN 251362-65-9 HCAPLUS

CN Glycine, L-threonyl-L-threonylglycyl-L-threonyl-L-methionyl-L-valyl-L-seryl-L-seryl-L-isoleucyl-L-α-aspartyl-L-seryl-L-α-glutamyl-L-lysyl-L-glutaminyl-L-α-aspartyl-L-seryl-L-prolyl-L-prolyl-L-prolyl-L-lysyl-L-prolyl-L-prolyl-L-arginyl-L-threonyl-L-arginyl-L-seryl-L-cysteinyl-L-leucyl-L-valyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



PAGE 2-B



PAGE 2-C



RN 251362-66-0 HCAPLUS
CN L-Arginine, L-glutaminyl-L-α-aspartyl-L-seryl-L-prolyl-L-prolyl-L-prolyl-L-lysyl-L-prolyl-L-prolyl-L-arginyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

PAGE 2-B



L18 ANSWER 24 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:736878 HCAPLUS
DOCUMENT NUMBER: 131:348536
TITLE: Human deadenylating nuclease, its isolation, production and usage for diagnosis and **therapy**
INVENTOR(S): Huls, Christoph; Gallert, Karl-Christian; Korner, Christof; Wahle, Elmar
PATENT ASSIGNEE(S): Aventis Research & Technologies GmbH & Co. KG, Germany
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9958647	A2	19991118	WO 1999-EP3071	19990505 <--
WO 9958647	A3	19991229		
W: AU, CA, CZ, HU, JP, KR, NZ, PL, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19822122	A1	19991223	DE 1998-19822122	19980508 <--
CA 2328492	AA	19991118	CA 1999-2328492	19990505 <--
AU 9942583	A1	19991129	AU 1999-42583	19990505 <--
AU 758898	B2	20030403		
EP 1084234	A2	20010321	EP 1999-941254	19990505 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002514410	T2	20020521	JP 2000-548439	19990505 <--
NZ 507993	A	20021220	NZ 1999-507993	19990505 <--

PRIORITY APPLN. INFO.: DE 1998-19822122 A 19980508 <--
WO 1999-EP3071 W 19990505 <--

AB The invention concerns the human deadenylating nuclease (DAN), its coding sequence, cloning, and expression; the application in gene **therapy**, diagnosis and antibody production The invention also concerns functional

variants of the enzyme. It can be applied for the diagnosis and **therapy** of various diseases, e.g. cancer, **autoimmune** diseases, allergies, etc.; for screening inhibitors and stimulants; and for vaccine production

IT **250590-84-2**
RL: PRP (Properties)
(unclaimed sequence; human deadenylating nuclease, its isolation, production and usage for diagnosis and **therapy**)

RN 250590-84-2 HCAPLUS

CN L-Arginine, L-phenylalanyl-L-prolyl-L-alanyl-L-isoleucyl-L-alanyl-L-leucyl-L-threonyl-L-phenylalanyl-L-valyl-L-arginyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L18 ANSWER 25 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:736745 HCAPLUS
DOCUMENT NUMBER: 131:350251
TITLE: Heavy chain dimers of HLA-B27 and their application in spondyloarthropathies
INVENTOR(S): Allen, Rachel Louise; Bowness, Paul; McMichael, Andrew James
PATENT ASSIGNEE(S): Isis Innovation Limited, UK
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9958557	A2	19991118	WO 1999-GB1481	19990511 <--
WO 9958557	A3	20000210		
W: AU, CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2331455	AA	19991118	CA 1999-2331455	19990511 <--
AU 9938390	A1	19991129	AU 1999-38390	19990511 <--
AU 759065	B2	20030403		
EP 1078055	A2	20010228	EP 1999-921016	19990511 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: GB 1998-10099 A 19980511 <--
WO 1999-GB1481 W 19990511 <--

AB The authors disclose dimers of HLA-B27 comprising two heavy chain polypeptides cross-linked by a disulfide bond involving cysteine residue 63. The heavy chain polypeptides comprise the extracellular domain portions of the HLA-B27 heavy chain and are capable of binding a HLA-B27 epitope. The dimers can be used to determine the onset of, or predisposition

to a spondyloarthropathy. The dimer can also be used as a **treatment** or prophylactic for a spondyloarthropathy.

IT **142479-13-8**
RL: PRP (Properties)
(unclaimed sequence; heavy chain dimers of HLA-B27 and their application in spondyloarthropathies)

RN 142479-13-8 HCAPLUS

CN L-Arginine, L-seryl-L-arginyl-L-tyrosyl-L-tryptophyl-L-alanyl-L-isoleucyl-L-arginyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L18 ANSWER 26 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:672991 HCAPLUS
DOCUMENT NUMBER: 131:308409

TITLE: Cloning and characterization of human STE20-related protein kinases and their diagnostic and **therapeutic** uses
INVENTOR(S): Plowman, Gregory; Martinez, Ricardo; Whyte, David
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 387 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9953036	A2	19991021	WO 1999-US8150	19990413 <--
WO 9953036	A3	20000511		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2369172	AA	19991021	CA 1999-2369172	19990413 <--
AU 9936424	A1	19991101	AU 1999-36424	19990413 <--
EP 1073723	A2	20010207	EP 1999-918539	19990413 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002522009	T2	20020723	JP 2000-543584	19990413 <--
US 2003050230	A1	20030313	US 1999-291417	19990413 <--
US 6680170	B2	20040120		
US 6656716	B1	20031202	US 2000-688188	20001016 <--
US 2004224323	A1	20041111	US 2003-725329	20031202 <--

PRIORITY APPLN. INFO.:			
US 1998-81784P	P	19980414	<--
US 1999-291417	A3	19990413	<--
WO 1999-US8150	W	19990413	<--
US 2000-688188	A3	20001016	<--

AB The present invention relates to the novel kinase polypeptides STLK2, STLK3, STLK4, STLK5, STLK6, STLK7, ZC1, ZC2, ZC3, ZC4, KHS2, SULU1, SULU3, GEK2, PAK4, and PAK5, nucleotide sequences encoding the novel kinase polypeptides, as well as various products and methods useful for the diagnosis and **treatment** of various kinase-related diseases and conditions. A targeted PCR cloning strategy and a "motif extraction" bioinformatics script were used to identify the new members of the STE20 kinase family. Multiple alignment and parsimony anal. of the catalytic domain of all of these STE20 family members reveals that these proteins cluster into 9 distinct subgroups. The present invention also includes the partial or complete sequence of these new members of the STE20 family, their classification, predicted or deduced protein structure, and a strategy for elucidating their biol. and **therapeutic** relevance. Many of the STE20-related kinase genes were mapped to regions associated with various human cancers, and the PAK5 gene exhibits a 3-fold amplification compared to the normal DNA copy number in PANC-1 (pancreatic epithelioid carcinoma) and OVCAR-3 (ovarian adenocarcinoma) human cell lines. Phage display data suggest potential interactions of SULU3 with SLK and SULU1 with GEK2 through their coiled-coil domains, thereby suggesting a specificity in interaction and implying that these STE20 kinases may interact with each other through homo-and hetero-dimerization. The STE20

family kinases may be of value (no data) in **treating** disease or disorder selected from the group consisting of immune-related diseases, myocardial infarction, cardiomyopathies, stroke, renal failure, and oxidative stress-related neurodegenerative disorders.

IT **247141-76-0 247141-79-3 247142-39-8**
RL: PRP (Properties)
(unclaimed protein sequence; cloning and characterization of human STE20-related protein kinases and their diagnostic and **therapeutic** uses)

RN 247141-76-0 HCAPLUS

CN L-Lysine, L-α-aspartyl-L-prolyl-L-arginyl-L-threonyl-L-arginyl-L-alanyl-L-seryl-L-α-aspartyl-L-prolyl-L-glutaminyl-L-seryl-L-prolyl-L-prolyl-L-glutaminyl-L-valyl-L-seryl-L-arginyl-L-histidyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 247141-79-3 HCAPLUS
CN L-Arginine, L-cysteinyl-L-prolyl-L-leucyl-L-methionyl-L-arginyl-L-glutaminyl-L-asparaginyl-L-arginyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 247142-39-8 HCAPLUS
CN L-Arginine, L-prolyl-L-leucyl-L-methionyl-L-arginyl-L-glutaminyl-L-asparaginyl-L-arginyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L18 ANSWER 27 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:671034 HCAPLUS
DOCUMENT NUMBER: 131:298664
TITLE: Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
INVENTOR(S): Bona, Constantin; Zaghouani, Habib
PATENT ASSIGNEE(S): USA
SOURCE: U.S., 62 pp., Cont.-in-part of U.S. Ser. No. 486,546, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5969109	A	19991019	US 1994-363276	19941222 <--
WO 9619584	A1	19960627	WO 1995-US16718	19951221 <--
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9646435	A1	19960710	AU 1996-46435	19951221 <--
PRIORITY APPLN. INFO.:			US 1990-486546 B2	19900228 <--
			US 1991-687376 B2	19910418 <--
			US 1994-327636 B2	19941024 <--
			US 1994-363276 A	19941222 <--
			WO 1995-US16718 W	19951221 <--

AB The present invention relates to chimeric antibodies which comprise a B cell epitope, a T cell epitope, and/or an antigen binding site. The chimeric antibodies may be produced by replacing at least a portion of an Ig mol. with the desired epitope or antigen binding site such that the functional capabilities of the epitope and the parent Ig are retained. The chimeric antibodies of the invention may be used to enhance an immune response against pathogens and tumor cells in subjects in need of such **treatment.** The antigen epitope is derived from HIV-1 gp120, V3 loop, V3C, or V3M; influenza hemagglutinin or NP protein; hepatitis virus pre-S1 antigen; measles virus F protein; foot and mouth disease virus VP1; etc.

IT **114416-42-1 160790-23-8**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chimeric antibodies comprising antigen binding sites and B and T cell epitopes for enhancing immune response against pathogens and tumor cells)
RN 114416-42-1 HCAPLUS
CN L-Proline, L-threonyl-L-tyrosyl-L-glutaminyl-L-arginyl-L-threonyl-L-arginyl-L-alanyl-L-leucyl-L-valyl-L-arginyl-L-threonylglycyl-L-methionyl-L-α-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 160790-23-8 HCAPLUS
CN Glycine, L-arginyl-L-arginyl-L-seryl-L-leucyl-L-seryl-L-isoleucylglycyl-L-prolylglycyl-L-arginyl-L-alanyl-L-phenylalanyl-L-arginyl-L-threonyl-L-arginyl-L-α-glutamyl-L-isoleucyl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



REFERENCE COUNT: 90 THERE ARE 90 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 28 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:495393 HCAPLUS
DOCUMENT NUMBER: 131:143513
TITLE: Methods and reagents for decreasing allergic reactions
INVENTOR(S): Sosin, Howard; Bannon, Gary A.; Burks, A. Wesley, Jr.; Sampson, Hugh A.
PATENT ASSIGNEE(S): University of Arkansas, USA; Mt. Sinai School of Medicine, University of New York
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9938978	A1	19990805	WO 1999-US2031	19990129 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2319437	AA	19990805	CA 1999-2319437	19990129 <--
AU 9923505	A1	19990816	AU 1999-23505	19990129 <--
AU 743647	B2	20020131		
EP 1051494	A1	20001115	EP 1999-903498	19990129 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

JP 2002501748	T2	20020122	JP 2000-529437		19990129 <--
AU 765211	B2	20030911	AU 2001-43769		20010508 <--
PRIORITY APPLN. INFO.:			US 1998-73283P	P	19980131 <--
			US 1998-74590P	P	19980213 <--
			US 1998-74624P	P	19980213 <--
			US 1998-74633P	P	19980213 <--
			US 1998-141220	A	19980827 <--
			AU 1996-72433	A3	19960923 <--
			WO 1999-US2031	W	19990129 <--

AB It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by masking the site with a compound that prevents IgE binding or by altering as little as a single amino acid within the protein, most typically a hydrophobic residue **towards** the center of the IgE-binding epitope, to eliminate IgE binding. The method allows the protein to be altered as minimally as possible, other than within the IgE-binding sites, while retaining the ability of the protein to activate T cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity. The examples use peanut allergens to demonstrate alteration of IgE binding sites. The critical amino acids within each of the IgE binding epitopes of the peanut protein that are important to Ig binding have been determined Substitution of even a single amino acid within each of the epitopes led to loss of IgE binding. Although the epitopes shared no common amino acid sequence motif, the hydrophobic residues located in the center of the epitope appeared to be most critical to IgE binding.

IT **191857-20-2**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(modified allergen with reduced IgE-binding and retaining T cell-activating and IgG-binding activities for decreasing allergic reactions)

RN 191857-20-2 HCAPLUS

CN Glycine, glycyl-L-α-glutamyl-L-arginyl-L-threonyl-L-arginylglycyl-L-arginyl-L-glutaminyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-A



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 29 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:483302 HCAPLUS
DOCUMENT NUMBER: 131:125480
TITLE: Bordetella pertussis filamentous hemagglutinin-based peptides which inhibit adhesion between leukocytes and endothelial cells
INVENTOR(S): Tuomanen, Elaine; Masure, H. Robert
PATENT ASSIGNEE(S): The Rockefeller University, USA
SOURCE: U.S., 82 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 5932217	A	19990803	US 1994-348353		19941130	<--
EP 584273	A1	19940302	EP 1992-913635		19920504	<--
EP 584273	B1	19981230				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE						
JP 06507641	T2	19940901	JP 1992-512001		19920504	<--
AU 664849	B2	19951207	AU 1992-21687		19920504	<--
AU 9221687	A1	19921221				
AT 175122	E	19990115	AT 1992-913635		19920504	<--
US 5792457	A	19980811	US 1995-465929		19950606	<--
US 5968512	A	19991019	US 1995-465965		19950606	<--
US 6015560	A	20000118	US 1995-465966		19950606	<--
PRIORITY APPLN. INFO.:			US 1994-247572	B2	19940523	<--
			US 1991-695613	A	19910503	<--
			WO 1992-US3725	W	19920504	<--
			US 1994-348353	A3	19941130	<--

AB Peptides which will inhibit the reaction between the RGD tripeptide of Bordetella pertussis filamentous hemagglutinin (FHA) and the integrin receptors of endothelial cells and their utility as **therapeutic** agents are described. FHA is discovered to comprise polypeptide regions with binding properties homologous to those of C3bi, blood-coagulation factor X, and an integrin receptor on endothelial cells. They are also antigenically related and antibodies to FHA cross-react with endothelial cells. Peptide regions of FHA can bind to leukocytes and competitively inhibit binding of Factor X or C3bi to leukocytes or leukocytes to endothelial cells. Significant consequences of these discoveries are: (1) peptides which contain or are analogs of the RGD region or one of the Factor X regions of FHA will bind to the CR3 integrin of leukocytes,

thereby preventing adherence of the leukocyte to endothelial cells in a procedure for lessening deleterious **inflammation**; (2) peptides or analogs which interact with leukocytes in competition with Factor X or C3bi can be used to inhibit blood coagulation or opsonization and phagocytosis; (3) antibodies to FHA will bind to homologous regions of normal proteins in animals; (4) peptides containing the carbohydrate recognition domain or analogs are optimal vaccines for whooping cough; and (5) peptides of each of the endothelial cell integrin receptor, Factor X, or C3bi domains of FHA are useful in vaccine quality control.

IT **233665-30-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Bordetella pertussis filamentous hemagglutinin-based peptides which inhibit adhesion between leukocytes and endothelial cells)
RN 233665-30-0 HCAPLUS
CN Glycine, glycyl-L-arginyl-L-threonyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 30 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:464188 HCAPLUS
DOCUMENT NUMBER: 131:101261
TITLE: Methods of using human receptor protein 4-1BB
INVENTOR(S): Kwon, Byoung S.
PATENT ASSIGNEE(S): Advanced Research and Technology Institute, Inc., USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9936093	A1	19990722	WO 1999-US823	19990114 <--
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6303121	B1	20011016	US 1998-7097	19980114 <--

CA 2318525	AA	19990722	CA 1999-2318525	19990114 <--
AU 9923204	A1	19990802	AU 1999-23204	19990114 <--
AU 764257	B2	20030814		
EP 1045701	A1	20001025	EP 1999-903099	19990114 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002531376	T2	20020924	JP 2000-539866	19990114 <--
PRIORITY APPLN. INFO.:			US 1998-7097 A	19980114 <--
			US 1993-12269 A2	19930201 <--
			US 1993-122796 B2	19930916 <--
			US 1995-409851 B2	19950323 <--
			WO 1999-US823 W	19990114 <--

AB Disclosed herein are methods of using the H4-1BB protein, ligands to this protein, and various mAbs either directed against H4-1BB or other mols. that can be used **therapeutically.** The nature and importance of the H4-1BB mol. provides the ligands and related co-stimulatory mols. the ability to enhance or suppress T cell activation and proliferation. By **treating** T cells that have expressed receptor protein H4-1BB with one of the four anti-H4-1BB monoclonal antibodies disclosed herein, activation or inhibition of the immune response is seen. Also disclosed herein is cDNA for the human receptor H4-1BB. The cDNA of the human receptor H4-1BB is about 65 % homologous to the mouse cDNA 4-1BB and was isolated by using probes derived from murine cDNA 4-1BB. A fusion protein for detecting cell membrane ligands to human receptor protein H4-1BB was developed. It comprises the extracellular portion of the receptor protein H4-1BB and a detection protein, alkaline phosphatase, bound to the portion of the receptor protein H4-1BB. B cells that have expressed a ligand to receptor protein H4-1BB can be **treated** with cells that have expressed receptor protein H4-1BB and B cell proliferation may be induced. The use of H4-1BB to block H4-1BB ligand binding has practical application in the suppression of the immune system during organ transplantation or against **autoimmune** diseases including diabetes, rheumatoid **arthritis**, and lupus. Other applications of this technol. include the development of **therapeutic** methods for the **treatment** of HIV-1 infected individuals, and the **treatment** of cancerous tumors.

IT **230626-69-4P**
RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation)
(H4-1BB containing; agonistic and antagonistic monoclonal antibodies to human receptor protein 4-1BB for **treating autoimmune** diseases, cancer, transplant rejection, and AIDS)

RN 230626-69-4 HCAPLUS

CN L-Threonine, L-phenylalanyl-L-α-glutamyl-L-arginyl-L-threonyl-L-arginyl-L-seryl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-prolyl-L-cysteinyl-L-seryl-L-asparaginyl-L-cysteinyl-L-prolyl-L-alanylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B



PAGE 2-C



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 31 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:603429 HCAPLUS
DOCUMENT NUMBER: 129:188355
TITLE: Antigens of viruses tropic for the mucous membrane and peptides derived from antibodies to them and their prophylactic, diagnostic, and **therapeutic** use
PATENT ASSIGNEE(S): Universite de Bourgogne, Fr.
SOURCE: Fr. Demande, 51 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2758331	A1	19980717	FR 1997-300	19970114 <--
FR 2758331	B1	19990305		
WO 9831807	A1	19980723	WO 1997-FR2433	19971226 <--
W: CA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 953050	A1	19991103	EP 1997-953956	19971226 <--
R: BE, CH, DE, DK, FR, GB, LI, SE, IE				

PRIORITY APPLN. INFO.: FR 1997-300 A 19970114 <--
WO 1997-FR2433 W 19971226 <--

AB Antigens of viruses tropic for mucous membranes, such as rotaviruses, are characterized and complementarity determining regions of antibodies raised against are characterized for use in the diagnosis, **treatment**, and prevention of infection. Monoclonal antibodies were raised against bovine rotavirus and **respiratory** syncytial virus by standard methods. CDNAs encoding the heavy and light chains were cloned by standard PCR methods and the CDRs identified. A series of peptides derived from the CDRs were synthesized by standard Fmoc chemical and tested for their ability to inhibit viral infection. A peptide effective against **respiratory** syncytial virus was identified. The monoclonal antibody from which the peptide was derived provided complete protection when used to passively immunize mice. The peptide itself was also effective.

IT **211624-47-4**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CDR peptide of monoclonal antibody to protein F of **respiratory** syncytial virus; antigens of viruses tropic for mucous membrane and peptides derived from antibodies to them and their prophylactic, diagnostic, and **therapeutic** use)

RN 211624-47-4 HCAPLUS

CN L-Alanine, L-lysyl-L-seryl-L-seryl-L-glutaminyl-L-seryl-L-leucyl-L-phenylalanyl-L-asparaginyl-L-threonyl-L-arginyl-L-threonyl-L-arginyl-L-lysyl-L-asparaginyl-L-tyrosyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B



PAGE 3-A



PAGE 4-A



L18 ANSWER 32 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:424096 HCAPLUS
DOCUMENT NUMBER: 129:94451
TITLE: Superantigen based methods and compositions for **treatment** of diseases
INVENTOR(S): Terman, David S.
PATENT ASSIGNEE(S): Terman, David S., USA
SOURCE: PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 9826747	A2	19980625	WO 1997-US23637		19971217	<--
W: CA, JP						
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE						
US 6340461	B1	20020122	US 1997-992877		19971217	<--
PRIORITY APPLN. INFO.:			US 1996-33172P	P	19961217	<--
			US 1997-44074P	P	19970417	<--

AB The present invention relates to **therapeutic** methods and compns. employing superantigens. Methods and compns. employing superantigens and **immunotherapeutic** proteins in combination with one another have been found to provide more effective **treatment** than either component used alone. Superantigens, in conjunction with one or more addnl. **immunotherapeutic** antigens, may be used to either induce a **therapeutic** immune response directed against a target or to inhibit a disease causing immune response. Specific combinations of superantigens and **immunotherapeutic** antigens are used to **treat** specific diseases. The induction (or augmentation) of a desired immune against a target may be used, for example, to kill cancer cells or kill the cells or an infectious agent. The inhibition of an immune response, e.g., through the induction of T cell anergy, may be used to reduce the symptoms of an **autoimmune** disease. Diseases that may be **treated** by the methods and compns. of the invention include neoplastic diseases, infectious diseases, and **autoimmune** diseases. One aspect of the invention is to provide methods for the **treatment** of diseases comprising the steps of administering an effective amount of a superantigen and an **immunotherapeutic** so as to have the desired **therapeutic** effect. The superantigen and **immunotherapeutic** antigen may be administered together as a mixture Alternatively, the superantigen and **immunotherapeutic** antigen

may be administered sep. In one embodiment of the invention, the superantigen and **immunotherapeutic** antigen are administered to the patient in the form of a **immunotherapeutic** antigen-superantigen polymer of the invention. Another aspect of the invention is to provide methods for the **treatment** of diseases comprising the steps of incubating a lymphocyte population ex **vivo** a superantigen and an **immunotherapeutic** protein so as to either activate or anergize T cells within the selected population.

IT **114416-46-5**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of superantigen and **immunotherapeutic** antigen for **treating** cancer and infection and **autoimmune** diseases)

RN 114416-46-5 HCAPLUS

CN Glycine, L-threonyl-L-tyrosyl-L-glutaminyl-L-arginyl-L-threonyl-L-arginyl-L-alanyl-L-leucyl-L-valyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L18 ANSWER 33 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:352866 HCAPLUS
DOCUMENT NUMBER: 129:50511
TITLE: PPT-C gene encoding substance Z tachykinin precursor

and **treatment** of substance Z-associated diseases.

INVENTOR(S): Paige, Christopher J.; Wu, Gillian E.; Zhang, Yu
PATENT ASSIGNEE(S): Wellesley Hospital Foundation, Can.
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9822497	A1	19980528	WO 1997-CA875	19971119 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2190679	AA	19980519	CA 1996-2190679	19961119 <--
CA 2271714	AA	19980528	CA 1997-2271714	19971119 <--
AU 9850446	A1	19980610	AU 1998-50446	19971119 <--
EP 941234	A1	19990915	EP 1997-913048	19971119 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.:
CA 1996-2190679 A 19961119 <--
WO 1997-CA875 W 19971119 <--

AB The present invention provides a mouse preprotachykinin C gene (PPT-C) which encodes a precursor protein for a new tachykinin peptide called Substance Z. Substance Z has vasodilative effects and is expressed in hematopoietic tissues. The identification and isolation of this peptide provides the basis for development of **therapeutic** strategies for immune disorders in which Substance Z is involved as well as for development of antibodies and antagonists for the peptide.

IT **208041-90-1 208041-91-2**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(substance Z; PPT-C gene encoding substance Z tachykinin precursor and **treatment** of substance Z-associated diseases)

RN 208041-90-1 HCAPLUS
CN L-Methioninamide, L-arginyl-L-seryl-L-arginyl-L-threonyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-tyrosylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A





RN 208041-91-2 HCAPLUS
CN L-Methioninamide, L-seryl-L-arginyl-L-threonyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-tyrosylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

NH_2

PAGE 2-A



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 34 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:650367 HCAPLUS
DOCUMENT NUMBER: 127:341810
TITLE: Peptides for integral membrane receptor and transporter antagonists, and **therapeutic** use thereof
INVENTOR(S): Ng, Gordon Y. K.; Seeman, Philip; George, Susan R.; O'Dowd, Brian F.
PATENT ASSIGNEE(S): Ng, Gordon Y. K., Can.; Seeman, Philip; George, Susan R.; O'Dowd, Brian F.
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9735881	A2	19971002	WO 1997-CA203	19970326 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,

LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ,
VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,
ML, MR, NE, SN, TD, TG

CA 2250567	AA	19971002	CA 1997-2250567	19970326 <--
AU 9720204	A1	19971017	AU 1997-20204	19970326 <--
EP 906339	A2	19990407	EP 1997-908101	19970326 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.:	US 1996-14306P	P	19960327 <--
	US 1996-670119	A	19960625 <--
	US 1996-24240P	P	19960820 <--
	WO 1997-CA203	W	19970326 <--

AB Specific antagonists for prokaryotic or eukaryotic integral membrane proteins are provided. The antagonists are peptides having the amino acid sequence of a transmembrane domain of the integral membrane proteins or of a portion or analog thereof. Methods are provided for preventing or **treating** disorders characterized by disordered function of an integral membrane protein by administration of a specific peptide antagonist of the integral membrane protein.

IT **197713-84-1**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides for integral membrane receptor and transporter antagonists, and **therapeutic** use thereof)

RN 197713-84-1 HCAPLUS

CN L-Histidine, L-leucyl-L-seryl-L-seryl-L-threonyl-L-seryl-L-prolyl-L-prolyl-L-α-glutamyl-L-arginyl-L-threonyl-L-arginyl-L-tyrosyl-L-seryl-L-prolyl-L-isoleucyl-L-prolyl-L-prolyl-L-seryl-L-histidyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



L18 ANSWER 35 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:372218 HCAPLUS
DOCUMENT NUMBER: 126:342445
TITLE: Transforming growth factor β1 and β2 antibodies, expression vectors, and use in **treatment** of fibrotic disease or immune/**inflammatory** disease
INVENTOR(S): Thomson, Julia Elizabeth; Vaughan, Tristan John; Williams, Andrew James; Green, Jonathan Alexander; Jackson, Ronald Henry; Bacon, Louise; Johnson, Kevin Stuart; Wilton, Alison Jane; Tempest, Philip Ronald; Pope, Anthony Richard; et al.
PATENT ASSIGNEE(S): Cambridge Antibody Technology Limited, UK; Thomson,

Julia Elizabeth; Vaughan, Tristan John
SOURCE: PCT Int. Appl., 186 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9713844	A1	19970417	WO 1996-GB2450	19961007 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG				
CA 2233042	AA	19970417	CA 1996-2233042	19961007 <--
GB 2305921	A1	19970423	GB 1996-20920	19961007 <--
GB 2305921	B2	19991020		
AU 9671405	A1	19970430	AU 1996-71405	19961007 <--
AU 702049	B2	19990211		
EP 853661	A1	19980722	EP 1996-932730	19961007 <--
EP 853661	B1	20000315		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 945464	A1	19990929	EP 1999-102166	19961007 <--
EP 945464	B1	20010207		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000500643	T2	20000125	JP 1997-514809	19961007 <--
AT 190650	E	20000415	AT 1996-932730	19961007 <--
ES 2146020	T3	20000716	ES 1996-932730	19961007 <--
PT 853661	T	20000831	PT 1996-932730	19961007 <--
AT 199091	E	20010215	AT 1999-102166	19961007 <--
ES 2156035	T3	20010601	ES 1999-102166	19961007 <--
PT 945464	T	20010731	PT 1999-102166	19961007 <--
GR 3033436	T3	20000929	GR 2000-401123	20000518 <--
GR 3035775	T3	20010731	GR 2001-400625	20010420 <--

PRIORITY APPLN. INFO.:			
	GB 1995-20486	A	19951006 <--
	GB 1996-1081	A	19960119 <--
	EP 1996-932730	A3	19961007 <--
	WO 1996-GB2450	W	19961007 <--

AB Specific binding members comprising human antibody antigen-binding domains specific for human transforming growth factor β (TGFβ) bind specifically isoforms TGFβ2 and TGFβ1 or both, preferentially compared with TGFβ3. Specific binding members may be isolated and utilized in the **treatment** of disease, particularly fibrotic disease and also immune-**inflammatory** diseases. **Therapeutic** utility is demonstrated using in vitro and in **vivo** models. Full sequence and binding information is provided, including epitope sequence information for a particularly advantageous specific binding member which binds the active form of TGFβ2, neutralizing its activity, but does not bind the latent form.

IT **189505-08-6P**
RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(TGF-β1-specific antibody 1B2 VH domain complementary determining region

CDR3 mutant; transforming growth factor β1 and β2 antibodies, expression vectors, and use in **treatment** of fibrotic disease or immune/**inflammatory** disease)

RN 189505-08-6 HCAPLUS

CN L-Tryptophan, L-alanyl-L-arginyl-L-threonyl-L-arginyl-L-α-glutamyl-L-tyrosyl-L-serylglycyl-L-histidyl-L-α-aspartyl-L-seryl-L-serylglycyl-L-valyl-L-α-aspartyl-L-α-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



L18 ANSWER 36 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1996:543887 HCAPLUS
DOCUMENT NUMBER: 125:193485
TITLE: HLA-binding oligopeptides as immunomodulator
INVENTOR(S): Matsushita, Sho; Nishimura, Taiji; Yone, Kenji; Yamaoka, Kazuyoshi; Yamada, Naoko; Motoki, Masamichi; Ogawa, Hiroko
PATENT ASSIGNEE(S): Teijin Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 61 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08151396	A2	19960611	JP 1994-292657	19941128 <--
PRIORITY APPLN. INFO.:			JP 1994-292657	19941128 <--

AB Disclosed are 570 HLA-DQ4-binding oligopeptides for use as immunomodulators and for **treatment** of chronic rheumatoid

arthritis, and prevention and **therapy** of virus infection and allergy.

IT **180734-56-9 180735-35-7 180735-45-9**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HLA-DQ4-binding oligopeptides for use as immunomodulators and for prevention and **therapy** of **arthritis** and viral infection and allergy)

RN 180734-56-9 HCAPLUS

CN L-Arginine, N2-[N-[N2-[N-[N2-[N-[N-[N2-[N-(N-L-alanyl-L-leucyl)-L-valyl]-L-lysyl]-L-tyrosyl]-L-leucyl]-L-lysyl]-L-tyrosyl]-L-arginyl]-L-threonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

PAGE 2-A



RN 180735-35-7 HCAPLUS
CN L-Arginine, N2-[N-[N2-[N-[N-[N2-[N-(1-glycyl-L-prolyl)glycyl]-L-arginyl]-L-alanyl]-L-phenylalanyl]-L-arginyl]-L-threonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 180735-45-9 HCAPLUS
CN L-Arginine, N2-[N2-[N-[N2-[N-[N-[N-[N-[N-[N-(N2-glycyl-L-glutaminyl)glycyl]-L-valyl]-L-seryl]-L-methionyl]-L-α-glutamyl]-L-tryptophyl]-L-arginyl]-L-threonyl]-L-arginyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



L18 ANSWER 37 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:497172 HCAPLUS
DOCUMENT NUMBER: 125:140551
TITLE: Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
INVENTOR(S): Bona, Constantin; Zaghouani, Habib
PATENT ASSIGNEE(S): Mount Sinai Sch. of Med. Univ. of New York, USA
SOURCE: PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9619584	A1	19960627	WO 1995-US16718	19951221 <--
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5969109	A	19991019	US 1994-363276	19941222 <--
AU 9646435	A1	19960710	AU 1996-46435	19951221 <--

PRIORITY APPLN. INFO.:

US 1994-363276	A	19941222 <--
US 1990-486546	B2	19900228 <--
US 1991-687376	B2	19910418 <--
US 1994-327636	B2	19941024 <--
WO 1995-US16718	W	19951221 <--

AB The present invention relates to chimeric antibodies which comprise a B cell epitope, a T cell epitope, and/or an antigen binding site. The chimeric antibodies may be produced by replacing at least a portion of an Ig mol. with the desired epitope or antigen binding site such that the functional capabilities of the epitope and the parent Ig are retained. The chimeric antibodies of the invention may be used as vaccine to enhance an immune response against pathogens and tumor cells in subjects in need of such **treatment.** Nucleic acid or DNA encoding sequence of the chimeric antibody or cell containing the DNA for **therapeutic** uses are also provided. In example, recombinant antibodies containing T cell epitope or B cell epitope of HIV gp120, HIV-1 HxB2 isolate, HIV-1 reverse transcriptase, influenza A virus hemagglutinin, etc. were prepared Also, chimeric Ig. containing influenza virus nucleoprotein cytotoxic T lymphocyte epitope and chimeric Ig. derivatized with polyethylene glycol were prepared for enhancing immune responses.

IT **114416-42-1 160790-23-8**
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chimeric antibodies comprising viral antigen binding sites and B and T cell epitopes as vaccine for enhancing immune responses)

RN 114416-42-1 HCAPLUS
CN L-Proline, L-threonyl-L-tyrosyl-L-glutaminyl-L-arginyl-L-threonyl-L-arginyl-L-alanyl-L-leucyl-L-valyl-L-arginyl-L-threonylglycyl-L-methionyl-L-α-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 160790-23-8 HCAPLUS
CN Glycine, L-arginyl-L-arginyl-L-seryl-L-leucyl-L-seryl-L-isoleucylglycyl-L-prolylglycyl-L-arginyl-L-alanyl-L-phenylalanyl-L-arginyl-L-threonyl-L-arginyl-L-α-glutamyl-L-isoleucyl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



L18 ANSWER 38 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:766963 HCAPLUS
DOCUMENT NUMBER: 123:167095
TITLE: Modulation of peptide binding by HLA-B27 polymorphism in pockets A and B, and peptide specificity of B*2703
AUTHOR(S): Villadangos, Jose A.; Galocha, Begona; Garcia, Fernando; Albar, Juan P.; Lopez de Castro, Jose A.
CORPORATE SOURCE: Facultad de Ciencias, Univ. Autonoma de Madrid, Madrid, Spain
SOURCE: European Journal of Immunology (**1995**), 25(8), 2370-7
CODEN: EJIMAF; ISSN: 0014-2980
PUBLISHER: VCH
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The results in this study address three aspects of peptide binding to the disease-associated antigen HLA-B27 and its modulation by polymorphism: the contribution of major anchor residues 2 and 9, the role of pocket B polymorphism in modulating peptide specificity, and the binding properties of B*2703, a subtype not found to be associated with spondyloarthropathy. Synthetic analogs of peptides naturally presented by B*2705 were used to demonstrate that residue 2 is essential, since Ala2 analogs bound marginally to B*2705, but the specificity of B*2705 for Arg2 is not absolute, and show that the contribution of basic residue 9 to binding was significant, but less than Arg2. The effect of single mutations in the B pocket was to decrease, or with the Glu > Met-45 mutation, totally shift pocket specificity for Arg2 **towards** other residues at this position. This was shown by quantitating the relative binding of Gln2 and Ala2 analogs, and by pool-sequencing of the peptides bound in **vivo** to these mutants. Peptides naturally presented by B*2705 apparently bound with a lower affinity to pocket A variants with altered hydrogen bonding to the peptide N terminus, including B*2703. Binding of peptide analogs with changes at positions 2 or 9 suggested that in B*2703 pocket A, interactions are weaker and pocket B interactions are stronger than in

B*2705. This can be explained by the effect of the unique His59 change in B*2703 in both pockets. Thus, B*2703 is probably the HLA-27 subtype with the most stringent specificity for the Arg2 peptide motif.

IT **142479-13-8**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(peptide binding modulation by HLA-B27 polymorphism in pockets A and B, and peptide specificity of B*2703)

RN 142479-13-8 HCAPLUS

CN L-Arginine, L-seryl-L-arginyl-L-tyrosyl-L-tryptophyl-L-alanyl-L-isoleucyl-L-arginyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L18 ANSWER 39 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:410557 HCAPLUS
DOCUMENT NUMBER: 123:136567
TITLE: Polypeptides that interact with other proteins and that include conformation-constraining groups flanking a protein-protein interaction site
INVENTOR(S): Evans, Herbert J.; Kini, R. Manjunatha
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 9425482	A1	19941110	WO 1994-US4294		19940421	<--
W: AU, BR, CA, JP, KR, NZ, US, US						
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE						
CA 2161108	AA	19941110	CA 1994-2161108		19940421	<--
AU 9467707	A1	19941121	AU 1994-67707		19940421	<--
US 5965698	A	19991012	US 1996-532818		19960503	<--
US 6100044	A	20000808	US 1997-934224		19970919	<--
US 6258550	B1	20010710	US 1999-413492		19991006	<--
PRIORITY APPLN. INFO.:			US 1993-51741	A	19930423	<--
			US 1993-143364	A	19931029	<--
			WO 1994-US4294	W	19940421	<--
			US 1996-532818	A3	19960503	<--
			US 1997-934224	A3	19970919	<--

AB Homologs and analogs of naturally-occurring polypeptides that contain one or more interaction sites of the natural counterpart with the interaction sites flanked by conformation-constraining moieties, such as proline or cysteine, are described for use as **therapeutics** or as investigative tools. These peptides may also contain non-protein groups that restrict free rotation. A series of derivs. of the RGD peptide were shown to inhibit collagen- or ADP-induced platelet aggregation.

IT **161502-84-7**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conformationally-constrained analog of peptide of prothrombin, as clotting inhibitor; peptides containing conformation-constraining groups that interact with other proteins and their **therapeutic** uses)

RN 161502-84-7 HCAPLUS
CN L-Lysine, L-isoleucyl-L-prolyl-L-lysyl-L-histidyl-L-seryl-L-arginyl-L-threonyl-L-arginyl-L-tyrosyl-L-prolyl-L-arginyl-L-asparaginyl-L-isoleucyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





L18 ANSWER 40 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:290075 HCAPLUS
DOCUMENT NUMBER: 122:97264
TITLE: Genes for serotonin receptors and uses of the genes and of the receptors
INVENTOR(S): Sutcliffe, J. Gregor; Erlander, Mark G.; Lovenberg, Timothy W.
PATENT ASSIGNEE(S): Scripps Research Institute, USA
SOURCE: PCT Int. Appl., 197 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9421670	A1	19940929	WO 1994-US2839	19940315 <--
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5968817	A	19991019	US 1993-31538	19930315 <--
AU 9465508	A1	19941011	AU 1994-65508	19940315 <--
EP 689548	A1	19960103	EP 1994-913288	19940315 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			US 1993-31538 A	19930315 <--
			WO 1994-US2839 W	19940315 <--

AB Genes encoding a number of human serotonin receptors are cloned and expressed for manufacture of the proteins to screen for biol. or pharmacol. active ligands of the receptors. Antibodies that are immunoreactive with the serotonin receptors are prepared Polypeptide serotonin receptor antagonists, oligonucleotide probes for detecting receptor genes, and nonhuman transgenic animals expressing the human receptor genes are also described. Partial cDNAs from rat hypothalamus were obtained by PCR using primers derived from transmembrane domains with particular attention paid to domains V and VI, which include the serotonin-binding region and differentiate the receptor from other G protein-coupled receptors. These were then screened with probes from non-conserved regions of serotonin receptors to obtain clones. These clones were then used to obtain corresponding human receptor cDNAs. The clones were successfully expressed in animal cell lines and the gene products purified. All of the rat clones tested were expressed in various structures of the hypothalamus but not in the cerebellum, **heart**, liver, or kidney. Pharmacol.

data for the receptors are presented.

IT **160161-78-4**
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(amino acid sequence; genes for serotoninergic receptors and their cloning and expression for diagnostic, **therapeutic**, and pharmacol. use)

RN 160161-78-4 HCAPLUS

CN L-Arginine, L-tryptophyl-L-threonyl-L-isoleucyl-L-threonyl-L-arginyl-L-histidyl-L-leucyl-L-glutaminyl-L-tyrosyl-L-threonyl-L-leucyl-L-arginyl-L-threonyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C

PAGE 2-A



PAGE 2-B



L18 ANSWER 41 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:200431 HCAPLUS
DOCUMENT NUMBER: 122:7948
TITLE: Manufacture with recombinant cells of proteins containing multiple antigenic determinants linked by flexible hinge domains and use of the chimeric proteins in vaccines
INVENTOR(S): Shen, De Fen; Wang, Chang Yi
PATENT ASSIGNEE(S): United Biomedical, Inc., USA
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9418234	A1	19940818	WO 1994-US1523	19940210 <--
W: AU, CA, JP, NO, RU, UA				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5683695	A	19971104	US 1993-15770	19930210 <--
AU 9461740	A1	19940829	AU 1994-61740	19940210 <--

PRIORITY APPLN. INFO.: US 1993-15770 A 19930210 <--
WO 1994-US1523 W 19940210 <--

AB The present invention relates to recombinant proteins encoding at least two antigenic epitopes joined by flexible hinge domains. Proteins of this design enable presentation of each epitope to the immune system and are particularly useful as vaccines against infectious agents, such as viruses, when many variants of that agent exist. Moreover, the recombinant proteins of the invention are useful as a single vaccine composition effective against diverse infectious agents since the subject proteins can have antigenic epitopes from different infectious agents. The invention further provides nucleic acids, expression vectors, host cells and methods for production of the subject recombinant proteins as well as vaccines and methods for **treating** HIV. An MEAV protein containing HIV-derived peptides separated by hinge peptides PPDPDP was produced with recombinant Escherichia coli. The HIV peptides were a portion of the CD4 binding site from the gp120 protein and different V3 loop epitopes from HIV-1 variants MN, SC, RF, IIIB, and WMJ2. Guinea pigs immunized with this protein produced antibodies displaying neutralization activity

for HIV-1MN.

IT **159126-48-4**
RL: PRP (Properties)
(epitope of V3 loop of HIV-1WMJ2 env protein; manufacture with E. coli of protein containing multiple HIV antigenic determinants linked by flexible hinge domains)

RN 159126-48-4 HCAPLUS

CN L-Glutamic acid, L-arginyl-L-seryl-L-leucyl-L-seryl-L-isoleucylglycyl-L-prolylglycyl-L-arginyl-L-alanyl-L-phenylalanyl-L-arginyl-L-threonyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





L18 ANSWER 42 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1994:599201 HCAPLUS
DOCUMENT NUMBER: 121:199201
TITLE: Substrate phosphorylation capacities of the major tyrosine protein kinase from the human promyelocytic cell line, HL-60
AUTHOR(S): Ernould, Anne-Pascale; Ferry, Gilles; Barret, Jean-Marc; Genton, Annie; Boutin, Jean A.
CORPORATE SOURCE: Dep. Exp. Oncol., Servier Res. Inst., Suresnes, Fr.
SOURCE: International Journal of Peptide & Protein Research (**1994**), 43(5), 496-504
CODEN: IJPPC3; ISSN: 0367-8377
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The major tyrosine protein kinase, HPK40, isolated from HL-60, the preparation of which is described elsewhere (Ernould, A. P., Ferry, G., Barret, J. M., Genton, A. and Boutin, J. A., Eur. J. Biochem., 214, 503-514), was investigated as to its specificity on a number of peptides and proteins. It was found that HPK40 can phosphorylate histones (except histone H4), casein, acid-**treated** enolase, actin and tubulin but not calmodulin. Phosphorylation specificity of HPK40 was investigated using over a hundred peptidic structures. HPK40 is not related to the 'src' family and does not phosphorylate efficiently either the tetrapeptide NEYT derived from the pp60src auto-phosphorylation domain or the corresponding peptide RRsrc, RRLIED-NEYTARG. VALYDYESR from the SH3 domain of pp60c-src is recognized as a substrate with a high phosphorylation level. DEDYIQD, derived from the phosvitin/casein kinase II, was also highly phosphorylated. In order to determine the minimal recognition sequence of HPK40, the phosphorylation of about 60 dito tetrapeptides was investigated. Some of the tetrapeptides, such as *EEYE and NEYE, were well phosphorylated. Even some tripeptides, such as EYE, DYM, TYS and KYE, were recognized by HPK40, while none of the tested dipeptides was recognized as substrate. Sequences of peptides from DRVYHPF (angiotensin), LEEEEEAYGWMDF (minigastrin) and QEEYSAM (from H-ras1) were examined as substrates. The presence of one or several acidic residues on the Nα-side of tyrosine residue was identified as the only apparently favorable determinant. These results are steps **towards** the min. recognition sequence, which in turn will serve as a lead for

chemical modifications in view of obtaining a specific, low-mol.-weight, inhibitor of this human tyrosine protein kinase.

IT **114416-46-5**
RL: BIOL (Biological study)
(tyrosine protein kinase HLK40 of human promyelocytic cell line HL-60 specificity for, structure relation to)

RN 114416-46-5 HCAPLUS

CN Glycine, L-threonyl-L-tyrosyl-L-glutaminyl-L-arginyl-L-threonyl-L-arginyl-L-alanyl-L-leucyl-L-valyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L18 ANSWER 43 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	1994:3558 HCAPLUS
DOCUMENT NUMBER:	120:3558
TITLE:	Thrombin receptor antagonists
INVENTOR(S):	Maraganore, John M.; Frelinger, Andrew L., III
PATENT ASSIGNEE(S):	Biogen, Inc., USA
SOURCE:	PCT Int. Appl., 95 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9318141	A1	19930916	WO 1993-US1901	19930302 <--
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9337866	A1	19931005	AU 1993-37866	19930302 <--
EP 632829	A1	19950111	EP 1993-907162	19930302 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07507995	T2	19950907	JP 1993-515850	19930302 <--
US 5446131	A	19950829	US 1994-328388	19941024 <--
PRIORITY APPLN. INFO.:			US 1992-847561	A2 19920302 <--
			WO 1993-US1901	A 19930302 <--

AB Peptides and peptide derivs. capable of binding to the hirudin-like domain (amino acids 52-69) of the thrombin receptor are described for use as antagonists of the receptor for **therapeutic** and prophylactic purposes. These compds. may be synthesized chemical; fusion proteins containing the antagonist and a second protein (e.g. a cytotoxin) may be manufactured by expression. A series of peptides were synthesized by standard BOC chemical and were shown to bind specifically to receptor-bearing cells with the binding antagonized by an analog of the anionic domain of the receptor. The IC50 values for these analogs in platelet aggregation assays were in the range 7-600 μM; allowing some of these peptides to cyclize by oxidation of a pair of cysteine residues affected the activity. These inhibitors did not affect the catalytic activity of thrombin or thrombin polymerization of fibrin.

IT **151369-67-4 151369-69-6 151369-71-0**
151369-72-1 151369-73-2 151369-74-3
151369-75-4 151369-80-1 151369-81-2
151369-82-3 151369-83-4 151369-84-5
RL: BIOL (Biological study)
(analog of hirudin-like domain, as thrombin receptor antagonist)

RN 151369-67-4 HCAPLUS

CN L-Glutamic acid, L-leucyl-L-valyl-L-arginyl-L-isoleucylglycyl-L-lysyl-L-histidyl-L-seryl-L-arginyl-L-threonyl-L-arginyl-L-tyrosyl-L-α-glutamyl-L-arginyl-L-asparaginyl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 3-A



RN 151369-69-6 HCAPLUS
CN L-Isoleucine, L-leucyl-L-cysteinyl-L-arginyl-L-isoleucylglycyl-L-lysyl-L-histidyl-L-seryl-L-arginyl-L-threonyl-L-arginyl-L-tyrosyl-L-α-

glutamyl-L-arginyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A





RN 151369-71-0 HCAPLUS
CN L-Isoleucine, L-leucyl-L-valyl-L-arginyl-L-isoleucylglycyl-L-lysyl-L-histidyl-L-seryl-L-arginyl-L-threonyl-L-arginyl-L-tyrosyl-L-α-glutamyl-L-arginyl-L-asparaginyl-L-isoleucyl-L-α-glutamyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 3-A



RN 151369-72-1 HCAPLUS
CN L-Isoleucine, L-leucyl-L-valyl-L-arginyl-L-isoleucylglycyl-L-ornithyl-L-histidyl-L-seryl-L-arginyl-L-threonyl-L-arginyl-L-tyrosyl-L-α-glutamyl-L-arginyl-L-asparaginyl-L-isoleucyl-L-α-glutamyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 3-A



RN 151369-73-2 HCAPLUS
CN L-Isoleucine, L-leucyl-L-valyl-L-arginyl-L-isoleucylglycyl-L-lysyl-L-histidyl-L-seryl-L-arginyl-L-threonyl-L-arginyl-L-tyrosyl-L-α-aspartyl-L-arginyl-L-asparaginyl-L-isoleucyl-L-α-glutamyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 3-A



RN 151369-74-3 HCAPLUS
CN L-Isoleucine, L-leucyl-L-valyl-N6-(aminoiminomethyl)-L-lysyl-L-isoleucylglycyl-L-lysyl-L-histidyl-L-seryl-L-arginyl-L-threonyl-L-arginyl-L-tyrosyl-L-α-glutamyl-L-arginyl-L-asparaginyl-L-isoleucyl-L-α-glutamyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 3-A



RN 151369-75-4 HCAPLUS
CN Glycine, L-leucyl-L-valyl-L-arginyl-L-isoleucylglycyl-L-lysyl-L-histidyl-L-seryl-L-arginyl-L-threonyl-L-arginyl-L-tyrosyl-L-α-glutamyl-L-arginyl-L-asparaginyl-L-isoleucyl-L-α-glutamyl-L-lysyl-3-cyclohexyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 151369-80-1 HCAPLUS
CN L-Isoleucine, N-[4-[(aminoiminomethyl)amino]benzoyl]-L-isoleucylglycyl-L-lysyl-L-histidyl-L-seryl-L-arginyl-L-threonyl-L-arginyl-L-tyrosyl-L-α-glutamyl-L-arginyl-L-asparaginyl-L-isoleucyl-L-α-glutamyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B



PAGE 2-A



PAGE 2-B



RN 151369-81-2 HCAPLUS
CN L-Isoleucine, L-leucyl-L-valyl-L-arginyl-D-cysteinylglycyl-L-lysyl-L-histidyl-L-seryl-L-arginyl-L-threonyl-L-arginyl-L-tyrosyl-L-α-glutamyl-L-arginyl-L-asparaginyl-L-cysteinyl-L-α-glutamyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 3-A



PAGE 4-A



RN 151369-82-3 HCAPLUS
CN L-Isoleucine, L-leucyl-L-valyl-L-arginyl-D-cysteinylglycyl-L-lysyl-L-histidyl-L-seryl-L-arginyl-L-threonyl-L-arginyl-L-tyrosyl-L-α-glutamyl-L-arginyl-L-asparaginyl-D-cysteinyl-L-α-glutamyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 3-A



PAGE 4-A



RN 151369-83-4 HCAPLUS
CN L-Asparagine, L-leucyl-L-valyl-L-arginyl-D-cysteinylglycyl-L-lysyl-L-histidyl-L-seryl-L-arginyl-L-threonyl-L-arginyl-L-tyrosyl-L-α-glutamyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C

PAGE 2-B



RN 151369-84-5 HCAPLUS
CN L-Asparagine, L-arginyl-L-isoleucylglycyl-L-lysyl-L-histidyl-L-seryl-L-arginyl-L-threonyl-L-arginyl-L-tyrosyl-L-α-glutamyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



L18 ANSWER 44 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1993:100357 HCAPLUS
DOCUMENT NUMBER: 118:100357
TITLE: Determination of allele-specific peptide sequences on MHC antigens
INVENTOR(S): Rammensee, Hans Georg; Falk, Kirsten; Roetzschke, Olaf; Stevanovic, Stefan; Jung, Guenther
PATENT ASSIGNEE(S): Max-Planck-Gesellschaft zur Foerderung der Wissenschaften eV, Germany
SOURCE: Ger. Offen., 17 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4116256	A1	19921119	DE 1991-4116256	19910517 <--
DE 4116256	C2	19960829		
DE 4143467	C2	19950209	DE 1991-4143467	19910517 <--
CA 2103148	AA	19921118	CA 1992-2103148	19920515 <--
WO 9221033	A1	19921126	WO 1992-EP1072	19920515 <--
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
AU 9216943	A1	19921230	AU 1992-16943	19920515 <--
EP 584136	A1	19940302	EP 1992-909723	19920515 <--
EP 584136	B1	20000202		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
JP 06510850	T2	19941201	JP 1992-509201	19920515 <--
JP 3424752	B2	20030707		
AT 189527	E	20000215	AT 1992-909723	19920515 <--
ES 2145007	T3	20000701	ES 1992-909723	19920515 <--
JP 2003176300	A2	20030624	JP 2002-357021	19920515 <--
US 5747269	A	19980505	US 1994-146145	19940509 <--
PRIORITY APPLN. INFO.:			DE 1991-4116256 A3	19910517 <--
			JP 1992-509201 A3	19920515 <--
			WO 1992-EP1072 A	19920515 <--

AB Allele-specific peptide sequences associated with class I or II MHC antigens are determined by immunopptn. of the antigens (with the associated peptides) from a cell extract using anti-MHC antibodies, separating the peptide mixture from the MHC antigens and other protein constituents, sequencing individual peptides or mixts. thereof, and deriving the allele-specific sequences from the information obtained, especially from sequencing mixts. Peptides with the derived sequences are useful for **treatment** of tumors and immune disorders such as **autoimmune** diseases, transplant rejection, and graft-vs.-host reactions. Thus, P815 tumor cells were lysed and the supernatant was passed through columns of Sepharose 4B-immobilized anti-H-2Kd antibody, Sepharose 4B-bound glycine, and Sepharose 4B-immobilized anti-H-2Db antibody for immunopptn. Bound peptides were released from the beads with F3CCO2H, subjected to reversed-phase HPLC, and sequenced as a mixture The consensus sequence for H-2Kd-bound peptides was consistent with a nonapeptide resembling the influenza epitope which binds naturally to H-2Kd, with Tyr at position 2 and Ile or Leu at position 9 as presumptive "anchor residues".

IT **132326-72-8D**, analogs
RL: BIOL (Biological study)
(H-2Kd antigen binding by)
RN 132326-72-8 HCAPLUS
CN L-Valine, L-threonyl-L-tyrosyl-L-glutaminyl-L-arginyl-L-threonyl-L-arginyl-L-alanyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



```
=> d que stat l18
L1                STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  29

STEREO ATTRIBUTES: NONE
L3          1567 SEA FILE=REGISTRY SSS FUL L1
L4           846 SEA FILE=HCAPLUS ABB=ON  L3
L5           131 SEA FILE=HCAPLUS ABB=ON  L4 AND (?AUTOIMMUN? OR ?INFLAMM? OR
                 ?ARTHRIT? OR ?HEART? OR ?CARDIAC? OR ?ISCHEMI? OR ?RESPIRAT?
                 OR ?ARDS? OR ?ASTHMA? OR ?EMPHYSEMA?)
L6           131 SEA FILE=HCAPLUS ABB=ON  L5 AND (PD<20031113 OR PRD<20031113)
L7            75 SEA FILE=HCAPLUS ABB=ON  L6 AND (?THERAP? OR ?TREAT? OR
                 ?VIVO?)
L18           44 SEA FILE=HCAPLUS ABB=ON  L7 AND (PD<20000406 OR PRD<20000406)
```

```
=> d his ful

     (FILE 'HOME' ENTERED AT 14:21:19 ON 14 DEC 2004)

     FILE 'REGISTRY' ENTERED AT 14:21:28 ON 14 DEC 2004
L1              STR
L2           14 SEA SSS SAM L1
L3         1567 SEA SSS FUL L1

     FILE 'HCAPLUS' ENTERED AT 14:29:57 ON 14 DEC 2004
L4          846 SEA ABB=ON  L3
L5          131 SEA ABB=ON  L4 AND (?AUTOIMMUN? OR ?INFLAMM? OR ?ARTHRIT? OR
                ?HEART? OR ?CARDIAC? OR ?ISCHEMI? OR ?RESPIRAT? OR ?ARDS? OR
                ?ASTHMA? OR ?EMPHYSEMA?)
L6          131 SEA ABB=ON  L5 AND (PD<20031113 OR PRD<20031113)
L7           75 SEA ABB=ON  L6 AND (?THERAP? OR ?TREAT? OR ?VIVO?)
L8            0 SEA ABB=ON  NIJKAMP FRANSISCUS/AU
                E NIJKAMP FRANCISCUS/AU
L9          131 SEA ABB=ON  ("NIJKAMP F P"/AU OR "NIJKAMP FRANCISCUS"/AU OR
                "NIJKAMP FRANCISCUS PETRUS"/AU)
L10         289 SEA ABB=ON  ("NIJKAMP F P"/AU OR "NIJKAMP FRANCISCUS"/AU OR
                "NIJKAMP FRANCISCUS PETRUS"/AU OR "NIJKAMP FRANS"/AU OR
                "NIJKAMP FRANS P"/AU)
                E PFISTER ROSSWELL ROBERT/AU
L11          25 SEA ABB=ON  ("PFISTER ROSSWELL ROBERT"/AU OR "PFISTER ROSWELL"/
                AU OR "PFISTER ROSWELL R"/AU)
                E HADDOX JEFFREY LYNN/AU
L12          12 SEA ABB=ON  ("HADDOX JEFFREY L"/AU OR "HADDOX JEFFREY LYNN"/AU)
                E BLALOCK JAMES EDWIN/AU
L13           5 SEA ABB=ON  "BLALOCK JAMES EDWIN"/AU
                E VILLAIN MATTEO/AU
L14          55 SEA ABB=ON  ("VILLAIN M"/AU OR "VILLAIN MARION"/AU OR "VILLAIN
                MATTEO"/AU)
L15           1 SEA ABB=ON  L10 AND L11 AND L12 AND L13 AND L14
                SELECT RN L15 1-1

     FILE 'REGISTRY' ENTERED AT 14:45:02 ON 14 DEC 2004
L16           5 SEA ABB=ON  (292171-04-1/BI OR 292171-05-2/BI OR 292171-06-3/BI
                 OR 300541-35-9/BI OR 300541-36-0/BI)

     FILE 'HCAPLUS' ENTERED AT 14:45:09 ON 14 DEC 2004
L17           1 SEA ABB=ON  L15 AND L16

L18          44 SEA ABB=ON  L7 AND (PD<20000406 OR PRD<20000406)
```